[{"id":6556,"date":"2026-11-05T06:30:00","date_gmt":"2026-11-05T06:30:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/interim-report-q3-2026\/"},"modified":"2026-11-05T06:30:00","modified_gmt":"2026-11-05T06:30:00","slug":"interim-report-q3-2026","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/","title":{"rendered":"Interim report Q3 2026"},"content":{"rendered":"
\n

FDA approval of EMCITATE\u00ae (tiratricol) in the U.S. marks a transformative quarter for Egetis<\/strong><\/p>\n

Financial overview July-September<\/strong>
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly net revenue MSEK 21.5 (17.4), +24% at constant exchange rates (CER)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly result MSEK -147.0 (-82.4)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash flow for the quarter MSEK -111.9 (-57.2)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash at the end of the quarter MSEK 266.5 (145.7)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Earnings per share before and after dilution SEK \u20110.3 (-0.2)<\/p>\n

Financial overview January-September<\/strong>
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Net revenue for the period MSEK 52.3 (44.6), +17% at CER
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Result for the period MSEK -350.4 (-222.8)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash flow for the period MSEK 45.6 (-200.6)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash at the end of the period MSEK 266.5 (145.7)
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Earnings per share before and after dilution SEK -0.8 (-0.6)<\/p>\n

Significant events during the quarter<\/strong>
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 FDA approved EMCITATE for treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency in the U.S.
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egetis RareLink\u2122, the EMCITATE patient support program, was launched in partnership with PANTHERx\u00ae Rare
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 A Rare Pediatric Disease Priority Review Voucher (PRV) was granted by FDA in connection with the approval of EMCITATE
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tiratricol was granted Orphan Drug Designation for MCT8 deficiency in Japan
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Presented EMCITATE clinical data at the European Thyroid Association (ETA) and the European Society for Paediatric Endocrinology (ESPE) congresses, including data from the Triac Trial II and ReTRIACt studies
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Collaboration and supply agreement for EMCITATE signed with Orspec Pharma for Australia and New Zealand<\/p>\n

Significant events after the quarter<\/strong>
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Largest retrospective study of tiratricol in RTH-beta, led by Erasmus Medical Center, was published, providing further scientific support for the continued development of tiratricol in this indication
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EMCITATE became commercially available in the U.S. for treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency
\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egetis, and its subsidiary Rare Thyroid Therapeutics International AB (RTTI), entered into an agreement to sell the PRV for MUSD 190 (approximately MSEK 1,900). Former owners of RTTI are entitled to approximately 50 percent of net proceeds of the PRV<\/p>\n

Comments from the CEO<\/strong>
\u00a0<\/strong>
FDA approval of EMCITATE\u00ae in the U.S.<\/strong>
<\/strong>The third quarter was a defining period for Egetis, culminating on September 28 with FDA\u00b4s approval of EMCITATE for the treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency. EMCITATE is the first and only approved treatment for patients with MCT8 deficiency in the U.S.
This is an achievement which I am immensely proud of. Above all, the approval represents an important milestone for patients living with MCT8 deficiency and their families, who until now have had no approved treatment option in the U.S. It also represents a transformational milestone for Egetis and marks the beginning of a new chapter as we transition fully into a commercial-stage rare disease company in the world's largest pharmaceutical market.
MCT8 deficiency is a devastating and life-limiting genetic disorder. Patients experience severe neurodevelopmental impairment combined with persistent peripheral thyrotoxicosis, and a median life expectancy of approximately 35 years. This underlines both the severity of the disease and the substantial unmet medical need that has motivated our work with EMCITATE.
The U.S. approval was supported by a comprehensive clinical development program, including ReTRIACt, Triac Trial I, Triac Trial II, the Erasmus Medical Center (EMC) Cohort Study and Survival Study, and the U.S. Expanded Access Program. I would once again like to thank the patients and families who participated in these studies, as well as the investigators, healthcare professionals, patient advocacy organizations, our collaborators and, of course, the entire Egetis team whose commitment made this achievement possible.<\/p>\n

U.S. commercial launch of EMCITATE<\/strong>
<\/strong>With approval secured, our immediate priority has been to make EMCITATE available to eligible patients in the U.S. as quickly and efficiently as possible.
I am proud to share that we initiated the U.S. launch on October 27, ahead of previously anticipated timelines. This achievement reflects the extensive commercial and operational preparations undertaken ahead of the FDA decision, enabling us to move rapidly following approval. We have already seen good traction among physicians for EMCITATE after the approval and the commercial availability announcements.
To support patients, caregivers and healthcare professionals from launch, we have implemented Egetis RareLink\u2122, our dedicated patient support program for EMCITATE. Through Egetis RareLink, we have established the access infrastructure, including specialty distribution and dedicated support resources, designed to help patients, caregivers and healthcare professionals navigate the treatment journey. We have also partnered with PANTHERx\u00ae Rare to support medication access, education, care coordination and ongoing treatment services.
For an ultra-rare disease such as MCT8 deficiency, making a medicine commercially available is only one part of the challenge. Connecting diagnosed patients and their treating physicians with treatment and supporting them through the access process will be central to successful commercialization. Therefore,
our objective extends beyond launching a medicine, to building an infrastructure capable of supporting the MCT8 deficiency community over the long term.
The FDA approval also resulted in Egetis receiving a Rare Pediatric Disease Priority Review Voucher, or PRV. On November 4, we entered into an agreement to sell the PRV for USD 190 million (approximately SEK 1.900 million). Former owners of Rare Thyroid Therapeutics International AB are entitled to approximately 50 percent of net proceeds of the PRV, as an earnout following Egetis\u2019 acquisition of EMCITATE\u00ae (tiratricol) in 2020.<\/p>\n

Commercialization of EMCITATE in the EU and international markets<\/strong>
<\/strong>The revenue for EMCITATE during the third quarter was MSEK 21.5, a 24 percent increase at constant exchange rates (CER), compared with the same quarter in 2025. The majority of sales originate from Germany, the first and only country where we have concluded a national reimbursement process, with the German national statutory health insurers, GKV-Spitzenverband. In Spain, we had a first meeting with the Ministry of Health during the quarter, to discuss our submitted national pricing and reimbursement dossier for EMCITATE. In Italy and France, we await the publication of survival data for EMCITATE by Erasmus Medical Center, to strengthen our value dossiers.
\u00a0<\/strong>
Markets outside the U.S. and Europe<\/strong>
On August 31, we announced that our partner in Japan, Fujimoto Pharmaceutical Corporation, which holds an exclusive license to develop and commercialize EMCITATE for MCT8 deficiency in Japan, had been granted Orphan Drug Designation for tiratricol by Japan\u2019s Ministry of Health, Labor and Welfare.
Among the benefits of this designation in Japan, a future marketing authorization application is eligible for Priority Review, reducing the review time from approximately twelve to nine months, and the market exclusivity period is extended to ten years. Tiratricol now holds Orphan Drug Designation for MCT8 deficiency in Japan, the U.S. and the EU. The NDA in Japan for EMCITATE is expected to be submitted in 2027.
Our distribution partner companies Er-Kim (Turkey, Central, Eastern, and Southeastern Europe) and taiba rare (Gulf region) are actively identifying patients in their respective territories and have initiated funded treatment to more patients. In the quarter we signed a collaboration and supply agreement with Orspec Pharma, to enable us to reach more patients with MCT8 deficiency in Australia and New Zealand.<\/p>\n

Raising visibility of clinical evidence and awareness of MCT8 deficiency<\/strong>
<\/strong>We also continued to strengthen communication of the scientific evidence supporting tiratricol during the quarter. In September, clinical data relating to EMCITATE were presented at the 47th Annual Meeting of the European Thyroid Association (ETA) in Porto, Portugal, and the 64th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE) in Marseille, France. The presentations included data from Triac Trial II examining early treatment in young pediatric patients with MCT8 deficiency and results from the ReTRIACt study evaluating the effects of tiratricol treatment withdrawal.
The continued presentations and publications of clinical evidence are important as awareness of MCT8 deficiency grows internationally. They support the medical community in understanding the disease and the role of tiratricol and provide an important scientific foundation as we work to broaden access to EMCITATE globally.
\u00a0<\/strong>
Exploring the potential of tiratricol in RTH-beta<\/strong>
Our work is also increasingly focused on the longer-term potential of tiratricol beyond MCT8 deficiency. Resistance to thyroid hormone beta (RTH-beta) is a separate indication from MCT8 deficiency, with no overlap between the patient populations, and tiratricol already holds Orphan Drug Designation for RTH-beta in both the U.S. and the EU. In October, the largest retrospective cohort study to date evaluating tiratricol in patients with RTH-beta, was published in eBioMedicine, a journal in the Lancet family. The international multicenter study, led by Erasmus Medical Center, included 28 patients aged from 0.4 to 73 years with 18 different THRB mutations. Median treatment duration was approximately four years. In this retrospective analysis, tiratricol was associated with statistically significant reductions in free thyroxine, or FT4, of 37 percent and thyroid stimulating hormone, or TSH, of 43 percent, together with a reduction in heart rate of 10 beats per minute.
These results further strengthen the scientific rationale for investigating tiratricol as a potential treatment for RTH-beta, a rare inherited thyroid hormone disorder for which there are currently no approved therapies. Tiratricol is investigational in RTH-beta and has not been approved by any regulatory authority for this indication.
We are continuing our work to finalize the development plan for tiratricol in RTH-beta. Scientific advisory boards have been convened, and preparations for regulatory interactions are ongoing. While MCT8 deficiency remains our immediate commercial focus, RTH-beta represents an opportunity to apply our growing expertise in rare thyroid hormone disorders to another patient population with significant unmet medical need.<\/p>\n

Cash <\/strong>
<\/strong>We report cash of MSEK 267 (MSEK 146) as of September 30, 2026. The sale of the PRV will provide a significant non-dilutive cash contribution, strengthening our financial flexibility as we accelerate the commercialization of EMCITATE in the U.S. and advance the RTH-beta program.
\u00a0<\/strong>
Outlook <\/strong>
<\/strong>2026 is a year marked by several important milestones for Egetis. Our team focuses on delivering three key priorities:<\/p>\n

\u2022 Successfully launch EMCITATE in the U.S.
\u2022 Optimize pricing and reimbursement and continue launch of EMCITATE in Europe
\u2022 Finalize the development plan for tiratricol in RTH-beta.<\/p>\n

Stockholm, Sweden, November 5, 2026
Nicklas Westerholm
CEO<\/p>\n<\/div>\n

\n

For further information, please contact<\/strong><\/p>\n

\n

Nicklas Westerholm, CEO
nicklas.westerholm@egetis.com
+46\u00a0(0) 733 542 062<\/p>\n

Yilmaz Mahshid, CFO
yilmaz.mahshid@egetis.com
+46 (0) 722\u00a0316\u00a0800<\/p>\n

Karl H\u00e5rd, Head of Investor Relations & Business Development
karl.hard@egetis.com
+46 (0) 733 011 944<\/p>\n<\/div>\n

\n

This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-05 07:30 CET.<\/em><\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n

\n

Q3 2026 Report ENG MASTER Nov 5<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"FDA approval of EMCITATE\u00ae (tiratricol) in the U.S. marks a transformative quarter for Egetis Financial overview July-September\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly net revenue MSEK 21.5 (17.4), +24% at constant exchange rates (CER)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly result MSEK -147.0 (-82.4)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash flow for the quarter MSEK -111.9 (-57.2)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash at the end of the quarter MSEK 266.5 (145.7)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Earnings per share […]","protected":false},"template":"","class_list":["post-6556","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-arc-event","mfn-news-tag-mfn-arc-event-report","mfn-news-tag-mfn","mfn-news-tag-mfn-report-interim-q3","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-report"],"acf":[],"yoast_head":"\nInterim report Q3 2026 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Interim report Q3 2026 - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"FDA approval of EMCITATE\u00ae (tiratricol) in the U.S. marks a transformative quarter for Egetis Financial overview July-September\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly net revenue MSEK 21.5 (17.4), +24% at constant exchange rates (CER)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly result MSEK -147.0 (-82.4)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash flow for the quarter MSEK -111.9 (-57.2)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash at the end of the quarter MSEK 266.5 (145.7)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Earnings per share […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/interim-report-q3-2026\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/interim-report-q3-2026\\\/\",\"name\":\"Interim report Q3 2026 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-05T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/interim-report-q3-2026\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/interim-report-q3-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/interim-report-q3-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Interim report Q3 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report Q3 2026 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/","og_locale":"sv_SE","og_type":"article","og_title":"Interim report Q3 2026 - Egetis Therapeutics","og_description":"FDA approval of EMCITATE\u00ae (tiratricol) in the U.S. marks a transformative quarter for Egetis Financial overview July-September\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly net revenue MSEK 21.5 (17.4), +24% at constant exchange rates (CER)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Quarterly result MSEK -147.0 (-82.4)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash flow for the quarter MSEK -111.9 (-57.2)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cash at the end of the quarter MSEK 266.5 (145.7)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Earnings per share […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"8 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/","url":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/","name":"Interim report Q3 2026 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-05T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/interim-report-q3-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Interim report Q3 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6557,"date":"2026-11-05T06:30:00","date_gmt":"2026-11-05T06:30:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/kvartalsrapport-q3-2026\/"},"modified":"2026-11-05T06:30:00","modified_gmt":"2026-11-05T06:30:00","slug":"kvartalsrapport-q3-2026","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/","title":{"rendered":"Kvartalsrapport Q3 2026"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>FDA-godk\u00e4nnandet av EMCITATE\u00ae (triatricol) i USA markerar ett transformativt kvartal f\u00f6r Egetis<\/strong><\/p>\n<p><strong>Finansiell \u00f6versikt juli-september<\/strong><br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets nettooms\u00e4ttning uppgick till MSEK 21,5 (17,4), +24% vid fasta valutakurser (CER)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets resultat uppgick till MSEK -147,0 (-82,4)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kassafl\u00f6det f\u00f6r kvartalet uppgick till MSEK -111,9 (-57,2)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Likvida medel vid kvartalets utg\u00e5ng uppgick till MSEK 266,5 (145,7)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Resultat per aktie f\u00f6re och efter utsp\u00e4dning uppgick till SEK -0,3 (-0,2)<\/p>\n<p><strong>Finansiell \u00f6versikt januari-september<\/strong><br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Nettooms\u00e4ttningen f\u00f6r perioden uppgick till MSEK 52,3 (44,6), +17% vid (CER)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Periodens nettoresultat uppgick till MSEK -350,4 (-222,8)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kassafl\u00f6det f\u00f6r perioden uppgick till MSEK 45,6 (-200,6)<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Likvida medel vid periodens utg\u00e5ng uppgick till MSEK 266,5 (145,7<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Resultat per aktie f\u00f6re och efter utsp\u00e4dning uppgick till SEK -0,8 (-0,6)<\/p>\n<p><strong>V\u00e4sentliga h\u00e4ndelser under kvartalet<\/strong><br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 FDA godk\u00e4nde EMCITATE f\u00f6r behandling av perifer tyreotoxikos hos patienter med MCT8-brist i USA<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egetis RareLink\u2122, patientst\u00f6dsprogrammet f\u00f6r EMCITATE, lanserades i samarbete med PANTHERx\u00ae Rare<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 FDA tilldelade en Rare Pediatric Disease Priority Review Voucher (PRV) i samband med godk\u00e4nnandet av EMCITATE<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tiratricol beviljades s\u00e4rl\u00e4kemedelsstatus (Orphan Drug Designation) f\u00f6r MCT8-brist i Japan<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kliniska data f\u00f6r EMCITATE presenterades vid European Thyroid Association (ETA) och European Society for Paediatric Endocrinology (ESPE) kongresserna, inklusive data fr\u00e5n studierna Triac Trial II och ReTRIACt<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Samarbets- och leveransavtal f\u00f6r EMCITATE tecknades med Orspec Pharma f\u00f6r Australien och Nya Zeeland<br \/><strong>\u00a0<\/strong><br \/><strong>V\u00e4sentliga h\u00e4ndelser efter kvartalet<\/strong><br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Den st\u00f6rsta retrospektiva studien av tiratricol vid RTH-beta publicerades och ger ytterligare vetenskapligt st\u00f6d f\u00f6r den fortsatta utvecklingen av tiratricol inom indikationen. Studien leddes av Erasmus Medical Center.<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 EMCITATE blev kommersiellt tillg\u00e4nglig i USA f\u00f6r behandling av perifer tyreotoxikos hos patienter med MCT8-brist<br \/>\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egetis, tillsammans med dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), tecknade avtal om f\u00f6rs\u00e4ljning av PRV f\u00f6r MUSD 190 (ca MSEK 1\u00a0900). Tidigare \u00e4gare av RTTI har r\u00e4tt till cirka 50 procent av nettoint\u00e4kterna fr\u00e5n PRV:n<\/p>\n<p><strong class=\"mfn-heading-1\">Vd har ordet<\/strong><br \/><strong><br \/><\/strong><strong>FDA godk\u00e4nde EMCITATE\u00ae i USA<\/strong><strong><br \/><\/strong>Det tredje kvartalet var en avg\u00f6rande period f\u00f6r Egetis och kulminerade den 28 september n\u00e4r FDA godk\u00e4nde EMCITATE f\u00f6r behandling av perifer tyreotoxikos hos patienter med MCT8-brist. EMCITATE \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r patienter med MCT8-brist i USA.<br \/>Detta \u00e4r en prestation som jag \u00e4r oerh\u00f6rt stolt \u00f6ver. Framf\u00f6r allt utg\u00f6r godk\u00e4nnandet en viktig milstolpe f\u00f6r patienter som lever med MCT8-brist och deras familjer, som fram till nu inte haft n\u00e5gon godk\u00e4nd behandlingsm\u00f6jlighet i USA. Det \u00e4r \u00e4ven en transformativ milstolpe f\u00f6r Egetis, och markerar b\u00f6rjan p\u00e5 ett nytt kapitel n\u00e4r vi tar steget till att fullt ut bli ett kommersiellt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar p\u00e5 v\u00e4rldens st\u00f6rsta l\u00e4kemedelsmarknad.<br \/>MCT8-brist \u00e4r en f\u00f6r\u00f6dande och livsf\u00f6rkortande genetisk sjukdom. Patienterna drabbas av sv\u00e5r neurologisk funktionsneds\u00e4ttning i kombination med best\u00e5ende perifer tyreotoxikos och har en medianlivsl\u00e4ngd p\u00e5 cirka 35 \u00e5r. Detta understryker b\u00e5de sjukdomens allvar och det betydande medicinska behov som har varit drivkraften bakom v\u00e5rt arbete med EMCITATE.<br \/>Det amerikanska godk\u00e4nnandet baserades p\u00e5 ett omfattande kliniskt utvecklingsprogram som inkluderade ReTRIACt, Triac Trial I, Triac Trial II, Erasmus Medical Centers (EMC) kohortstudie och \u00f6verlevnadsstudie samt det amerikanska Expanded Access programmet. Jag vill \u00e5terigen rikta ett stort tack till de patienter och familjer som deltagit i dessa studier, liksom till pr\u00f6vare, v\u00e5rdpersonal, patient-organisationer, v\u00e5ra samarbetspartners och naturligtvis hela Egetis-teamet vars engagemang gjort denna prestation m\u00f6jlig.<\/p>\n<p><strong>Kommersiell lansering av EMCITATE i USA<\/strong><strong><br \/><\/strong>Efter godk\u00e4nnandet har v\u00e5r h\u00f6gsta prioritet varit att g\u00f6ra EMCITATE tillg\u00e4ngligt f\u00f6r patienter i USA s\u00e5 snabbt och effektivt som m\u00f6jligt. Jag \u00e4r stolt \u00f6ver att kunna meddela att vi initierade lanseringen i USA den 27 oktober, vilket \u00e4r tidigare \u00e4n v\u00e5r f\u00f6rv\u00e4ntade tidplan. Denna prestation speglar de omfattande kommersiella och operativa f\u00f6rberedelser som genomf\u00f6rdes inf\u00f6r FDA:s beslut, vilket gjorde det m\u00f6jligt f\u00f6r oss att agera snabbt efter godk\u00e4nnandet. Vi har redan sett en positiv respons fr\u00e5n f\u00f6rskrivande l\u00e4kare f\u00f6r EMCITATE efter FDA-godk\u00e4nnandet och lanseringen p\u00e5 den amerikanska marknaden.<br \/>F\u00f6r att st\u00f6dja patienter, anh\u00f6riga och h\u00e4lso- och sjukv\u00e5rdspersonal redan fr\u00e5n lanseringen, introducerade vi Egetis RareLink\u2122, v\u00e5rt dedikerade patientst\u00f6dsprogram f\u00f6r EMCITATE. Genom Egetis RareLink har vi etablerat den infrastruktur som kr\u00e4vs f\u00f6r att ge patienter tillg\u00e5ng till l\u00e4kemedlet. Detta innefattar specialiserad distribution och dedikerade st\u00f6dfunktioner, utformade f\u00f6r att hj\u00e4lpa patienter, anh\u00f6riga och v\u00e5rdpersonal genom hela behandlingsresan. Vi har dessutom ing\u00e5tt partnerskap med PANTHERx\u00ae Rare f\u00f6r att st\u00f6dja tillg\u00e5ng till l\u00e4kemedlet, utbildning, v\u00e5rdkoordination och l\u00f6pande behandlingsst\u00f6d.<br \/>F\u00f6r en ultras\u00e4llsynt sjukdom som MCT8-brist \u00e4r det bara en del av utmaningen att g\u00f6ra ett l\u00e4kemedel kommersiellt tillg\u00e4ngligt. Att identifiera patienter och deras behandlande l\u00e4kare, koppla dem till behandling och st\u00f6dja dem genom processen f\u00f6r tillg\u00e5ng till l\u00e4kemedlet kommer att vara avg\u00f6rande f\u00f6r en framg\u00e5ngsrik kommersialisering. D\u00e4rf\u00f6r str\u00e4cker sig v\u00e5rt m\u00e5l l\u00e4ngre \u00e4n lansering av l\u00e4kemedlet. Vi vill ocks\u00e5 bygga en infrastruktur som l\u00e5ngsiktigt kan st\u00f6dja dem som lever med MCT8-brist.<br \/>FDA-godk\u00e4nnandet resulterade \u00e4ven i att Egetis erh\u00f6ll en Rare Pediatric Disease Priority Review Voucher (PRV). Den 4 november ingick vi ett avtal om att s\u00e4lja PRV:n till ett v\u00e4rde av MUSD 190 (ca MSEK 1\u00a0900). Tidigare \u00e4gare av Rare Thyroid Therapeutics International AB har r\u00e4tt till cirka 50 procent av nettoint\u00e4kterna fr\u00e5n PRV:n i form av en till\u00e4ggsk\u00f6peskilling efter Egetis f\u00f6rv\u00e4rv av EMCITATE\u00ae (tiratricol) 2020.<br \/>\u00a0<br \/><strong>Kommersialisering av EMCITATE i EU och internationella marknader<\/strong><strong><br \/><\/strong>Oms\u00e4ttningen fr\u00e5n f\u00f6rs\u00e4ljningen av EMCITATE uppgick under tredje kvartalet till MSEK 21,5, vilket motsvarar en \u00f6kning med 24 procent vid fasta valutakurser j\u00e4mf\u00f6rt med samma period 2025. Merparten av f\u00f6rs\u00e4ljningen kommer fr\u00e5n Tyskland, det f\u00f6rsta och enda landet d\u00e4r vi har slutf\u00f6rt en nationell subventionsprocess med den tyska sjukf\u00f6rs\u00e4kringsorganisationen GKV-Spitzenverband om att f\u00e5 l\u00e4kemedlet subventionerat. Under kvartalet hade vi ett f\u00f6rsta m\u00f6te med h\u00e4lsoministeriet i Spanien f\u00f6r att diskutera den nationella priss\u00e4ttnings- och ers\u00e4ttningsans\u00f6kan som vi l\u00e4mnat in f\u00f6r EMCITATE. <br \/>I Italien och Frankrike inv\u00e4ntar vi publiceringen av \u00f6verlevnadsdata f\u00f6r EMCITATE fr\u00e5n Erasmus Medical Center f\u00f6r att ytterligare st\u00e4rka v\u00e5r ans\u00f6kan.<\/p>\n<p><strong>Marknader utanf\u00f6r USA och Europa<\/strong><strong><br \/><\/strong>Den 31 augusti meddelade vi att v\u00e5r partner i Japan, Fujimoto Pharmaceutical Corporation, som innehar den exklusiva licensen att utveckla och kommersialisera EMCITATE f\u00f6r MCT8-brist i Japan, hade beviljats s\u00e4rl\u00e4kemedelsstatus (Orphan Drug Designation) f\u00f6r tiratricol av Japans h\u00e4lso-, arbetsmarknads- och v\u00e4lf\u00e4rdsministerium (Ministry of Health, Labor and Welfare). Bland f\u00f6rdelarna med denna status kan n\u00e4mnas att en framtida ans\u00f6kan om marknadsgodk\u00e4nnande kommer att vara ber\u00e4ttigad till prioriterad granskning, vilket f\u00f6rkortar handl\u00e4ggningstiden fr\u00e5n cirka tolv till nio m\u00e5nader. Dessutom f\u00f6rl\u00e4ngs marknadsexklusiviteten till tio \u00e5r. Tiratricol har nu s\u00e4rl\u00e4kemedelsstatus f\u00f6r MCT8-brist i Japan, USA och EU. Ans\u00f6kan om marknads-godk\u00e4nnande (NDA) f\u00f6r EMCITATE i Japan f\u00f6rv\u00e4ntas l\u00e4mnas in under 2027.<br \/>V\u00e5ra distributionspartners Er-Kim (Turkiet samt Central-, \u00d6st- och Syd\u00f6steuropa) och taiba rare (Gulfregionen) arbetar aktivt med att identifiera patienter inom sina respektive territorier och har ut\u00f6kat antalet patienter som f\u00e5r finansierad behandling. I kvartalet tecknade vi ett samarbets- och leveransavtal med Orspec Pharma f\u00f6r att kunna n\u00e5 fler patienter med MCT8-brist i Australien och Nya Zeeland.<br \/><strong>\u00a0<\/strong><br \/><strong>\u00d6kad synlighet f\u00f6r klinisk evidens och \u00f6kad medvetenhet om MCT8-brist<\/strong><strong><br \/><\/strong>Vi fortsatte \u00e4ven att st\u00e4rka kommunikationen av den vetenskapliga evidensen f\u00f6r tiratricol under kvartalet. <br \/>I september presenterades kliniska data f\u00f6r EMCITATE vid European Thyroid Associations (ETA) 47:e \u00e5rsm\u00f6te i Porto, Portugal, samt vid European Society for <br \/>Paediatric Endocrinologys (ESPE) 64:e \u00e5rsm\u00f6te i \u00a0\u00a0Marseille, Frankrike. Presentationerna omfattade bland annat data fr\u00e5n Triac Trial II, som unders\u00f6ker tidig behandling av sm\u00e5 barn med MCT8-brist, samt resultat fr\u00e5n ReTRIACt-studien, som utv\u00e4rderar effekterna av att avbryta behandling med tiratricol.<br \/>Fortsatta presentationer och publiceringar av klinisk evidens \u00e4r viktiga i takt med att kunskapen om MCT8-brist \u00f6kar internationellt. Det bidrar till att f\u00f6rb\u00e4ttra f\u00f6rst\u00e5elsen f\u00f6r sjukdomen och tiratricols roll inom det medicinska omr\u00e5det samt utg\u00f6r en viktig vetenskaplig grund i v\u00e5rt arbete med att bredda tillg\u00e5ngen till EMCITATE globalt.<\/p>\n<p><strong>Utforskar potentialen hos tiratricol i RTH-beta<\/strong><strong><br \/><\/strong>V\u00e5rt arbete fokuserar i allt h\u00f6gre grad \u00e4ven p\u00e5 den l\u00e5ngsiktiga potentialen f\u00f6r tiratricol bortom MCT8-brist.<strong> <\/strong>Resistens mot sk\u00f6ldk\u00f6rtelhormon beta (RTH-beta) \u00e4r en separat indikation fr\u00e5n MCT8-brist och har ingen \u00f6verlappning mellan patientpopulationerna, och tiratricol har redan erh\u00e5llit s\u00e4rl\u00e4kemedelsstatus f\u00f6r RTH-beta i b\u00e5de USA och EU. I oktober publicerades den hittills st\u00f6rsta retrospektiva kohortstudien som utv\u00e4rderar tiratricol hos patienter med RTH-beta i eBioMedicine, en tidskrift inom Lancet-gruppen. Den internationella studien, som leddes av Erasmus Medical Center, genomf\u00f6rdes p\u00e5 flera kliniker omfattade 28 patienter i \u00e5ldrarna 0,4 till 73 \u00e5r med 18 olika THRB-mutationer. Medianbehandlingstiden var cirka fyra \u00e5r. I den h\u00e4r retrospektiva analysen, visade sig behandling med tiratricol vara associerad med statistiskt signifikanta minskningar av fritt tyroxin (FT4) med 37 procent och tyreoideastimulerande hormon (TSH) med 43 procent, samtidigt som hj\u00e4rtfrekvensen minskade med i genomsnitt 10 slag per minut.<br \/>Resultaten st\u00e4rker ytterligare den vetenskapliga grunden f\u00f6r att utv\u00e4rdera tiratricol som en potentiell behandling f\u00f6r RTH-beta, en s\u00e4llsynt \u00e4rftlig sk\u00f6ldk\u00f6rtelhormon-relaterad sjukdom d\u00e4r det i dag saknas godk\u00e4nda behandlingar. Tiratricol \u00e4r under klinisk utveckling f\u00f6r RTH-beta och har \u00e4nnu inte godk\u00e4nts av n\u00e5gon regulatorisk myndighet f\u00f6r denna indikation.<br \/>Vi forts\u00e4tter arbetet med att f\u00e4rdigst\u00e4lla utvecklingsplanen f\u00f6r tiratricol inom RTH-beta. Vetenskapliga r\u00e5dgivande expertgrupper har sammankallats och f\u00f6rberedelser inf\u00f6r regulatoriska interaktioner p\u00e5g\u00e5r. \u00c4ven om MCT8-brist och kommersialisering av EMCITATE \u00e4r v\u00e5ra huvudfokus representerar RTH-beta en m\u00f6jlighet att till\u00e4mpa v\u00e5r v\u00e4xande expertis inom s\u00e4llsynta sk\u00f6ldk\u00f6rtelhormon-sjukdomar p\u00e5 ytterligare en patientgrupp med betydande medicinska behov.<br \/><strong>\u00a0<\/strong><br \/><strong>Kassaposition<\/strong><strong><br \/><\/strong>Per den 30 september 2026 uppgick likvida medel till MSEK 267 (146).<strong> <\/strong>F\u00f6rs\u00e4ljningen av PRV:n kommer att inneb\u00e4ra ett betydande, icke-utsp\u00e4dande, kapitaltillskott som st\u00e4rker v\u00e5r finansiella flexibilitet i takt med att vi accelererar kommersialiseringen i USA och avancerar RTH-beta-programmet.<\/p>\n<p><strong>Utsikter<\/strong><strong><br \/><\/strong>2026 \u00e4r ett \u00e5r pr\u00e4glat av flera viktiga milstolpar f\u00f6r Egetis. V\u00e5rt team fokuserar p\u00e5 tre prioriterade omr\u00e5den:<\/p>\n<p>\u2022 Framg\u00e5ngsrikt lansera EMCITATE i USA<br \/>\u2022 Optimera pris- och ers\u00e4ttningsniv\u00e5er samt forts\u00e4tta lanseringen i Europa<br \/>\u2022 F\u00e4rdigst\u00e4lla utvecklingsplanen f\u00f6r tiratricol i RTH-beta<\/p>\n<p>Stockholm den 5 november 2026<br \/>Nicklas Westerholm, VD<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-7a7f51f1d6b7\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta<\/strong><\/p>\n<hr \/>\n<p>Nicklas Westerholm, VD<br \/>nicklas.westerholm@egetis.com<br \/>\u00a0+46\u00a0(0) 733 542 062<\/p>\n<p>Yilmaz Mahshid, CFO<br \/>yilmaz.mahshid@egetis.com<br \/>+46 (0) 722\u00a0316\u00a0800<\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations & Business Development<br \/>karl.hard@egetis.com<br \/>+46 (0) 733 011 944<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Egetis Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2026-11-05 07:30 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/aab83025-5f32-4535-b7b0-3f35bec5c2e2\/q3-2026-report-swe-master-nov-5.pdf\" rel=\"noopener\" target=\"_blank\">Q3 2026 Report SWE MASTER Nov 5<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"FDA-godk\u00e4nnandet av EMCITATE\u00ae (triatricol) i USA markerar ett transformativt kvartal f\u00f6r Egetis Finansiell \u00f6versikt juli-september\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets nettooms\u00e4ttning uppgick till MSEK 21,5 (17,4), +24% vid fasta valutakurser (CER)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets resultat uppgick till MSEK -147,0 (-82,4)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kassafl\u00f6det f\u00f6r kvartalet uppgick till MSEK -111,9 (-57,2)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Likvida medel vid kvartalets utg\u00e5ng uppgick till MSEK 266,5 (145,7)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Resultat per aktie […]","protected":false},"template":"","class_list":["post-6557","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-arc-event","mfn-news-tag-mfn-arc-event-report","mfn-news-tag-mfn","mfn-news-tag-mfn-report-interim-q3","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-report","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kvartalsrapport Q3 2026 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Kvartalsrapport Q3 2026 - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"FDA-godk\u00e4nnandet av EMCITATE\u00ae (triatricol) i USA markerar ett transformativt kvartal f\u00f6r Egetis Finansiell \u00f6versikt juli-september\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets nettooms\u00e4ttning uppgick till MSEK 21,5 (17,4), +24% vid fasta valutakurser (CER)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets resultat uppgick till MSEK -147,0 (-82,4)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kassafl\u00f6det f\u00f6r kvartalet uppgick till MSEK -111,9 (-57,2)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Likvida medel vid kvartalets utg\u00e5ng uppgick till MSEK 266,5 (145,7)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Resultat per aktie […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/kvartalsrapport-q3-2026\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/kvartalsrapport-q3-2026\\\/\",\"name\":\"Kvartalsrapport Q3 2026 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-05T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/kvartalsrapport-q3-2026\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/kvartalsrapport-q3-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/kvartalsrapport-q3-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Kvartalsrapport Q3 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kvartalsrapport Q3 2026 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/","og_locale":"sv_SE","og_type":"article","og_title":"Kvartalsrapport Q3 2026 - Egetis Therapeutics","og_description":"FDA-godk\u00e4nnandet av EMCITATE\u00ae (triatricol) i USA markerar ett transformativt kvartal f\u00f6r Egetis Finansiell \u00f6versikt juli-september\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets nettooms\u00e4ttning uppgick till MSEK 21,5 (17,4), +24% vid fasta valutakurser (CER)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kvartalets resultat uppgick till MSEK -147,0 (-82,4)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kassafl\u00f6det f\u00f6r kvartalet uppgick till MSEK -111,9 (-57,2)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Likvida medel vid kvartalets utg\u00e5ng uppgick till MSEK 266,5 (145,7)\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Resultat per aktie […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"10 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/","url":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/","name":"Kvartalsrapport Q3 2026 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-05T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/kvartalsrapport-q3-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Kvartalsrapport Q3 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6557","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6557"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6550,"date":"2026-11-05T06:15:00","date_gmt":"2026-11-05T06:15:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/"},"modified":"2026-11-05T06:15:00","modified_gmt":"2026-11-05T06:15:00","slug":"uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/","title":{"rendered":"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><em><strong>Styrelsen f\u00f6r Egetis rekommenderar enh\u00e4lligt aktie\u00e4garna i Egetis och innehavaren av Konvertibeln och Teckningsoptionerna att acceptera ANI:s offentliga uppk\u00f6pserbjudande, baserat p\u00e5 den utv\u00e4rdering som redovisas nedan.<\/strong><\/em><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>Bakgrund<\/strong><br \/>Detta uttalande g\u00f6rs av styrelsen f\u00f6r Egetis Therapeutics AB (publ) (\u201d<strong>Egetis<\/strong>\u201d eller \u201d<strong>Bolaget<\/strong>\u201d) (\u201d<strong>Styrelsen<\/strong>\u201d) i enlighet med punkt II.19 i Takeover-reglerna f\u00f6r Nasdaq Stockholm och Nordic Growth Market NGM (\u201d<strong>Takeover-reglerna<\/strong>\u201d).<\/p>\n<p>ANI Pharmaceuticals, Inc., ett amerikanskt bolag med s\u00e4te i Delaware vars aktier \u00e4r upptagna till handel p\u00e5 Nasdaq Global Market i USA under kortnamnet \u201dANIP\u201d (\u201d<strong>ANI<\/strong>\u201d), har idag offentliggjort ett kontant offentligt uppk\u00f6pserbjudande till aktie\u00e4garna i Egetis och till innehavaren av konvertibell\u00e5net 2023:1 (\u201d<strong>Konvertibeln<\/strong>\u201d) och teckningsoptionerna 2023\/2033:1 (\u201d<strong>Teckningsoptionerna<\/strong>\u201d) utgivna av Egetis att \u00f6verl\u00e5ta samtliga sina aktier i Egetis och Konvertibeln och Teckningsoptionerna till ANI mot ett vederlag om 11,25 kronor kontant per aktie i Egetis och 65 750 817 kronor kontant f\u00f6r Konvertibeln, avseende dess nominella belopp om 3 miljoner euro, samt 6,99 kronor kontant per Teckningsoption (\u201d<strong>Erbjudandet<\/strong>\u201d). Erbjudandets totala v\u00e4rde uppg\u00e5r till cirka 5\u00a0304 miljoner kronor.[1]<\/p>\n<p><strong>Priset per aktie i Erbjudandet motsvarar en premie om:<\/strong><\/p>\n<ul>\n<li>cirka 12,6 procent j\u00e4mf\u00f6rt med st\u00e4ngningskursen om 9,99 kronor f\u00f6r en Egetis-aktie p\u00e5 Nasdaq Stockholm den 4 november 2026, vilket var den sista handelsdagen f\u00f6re offentligg\u00f6randet av Erbjudandet;<\/li>\n<li>cirka 27,0 procent j\u00e4mf\u00f6rt med den volymviktade genomsnittskursen om 8,86 kronor f\u00f6r en Egetis-aktie p\u00e5 Nasdaq Stockholm under de senaste 60 handelsdagarna f\u00f6re offentligg\u00f6randet av Erbjudandet; och<\/li>\n<li>cirka 48,0 procent j\u00e4mf\u00f6rt med den volymviktade genomsnittskursen om 7,60 kronor f\u00f6r en Egetis-aktie p\u00e5 Nasdaq Stockholm under de senaste 180 handelsdagarna f\u00f6re offentligg\u00f6randet av Erbjudandet.<\/li>\n<\/ul>\n<p>ANI kommer inte att h\u00f6ja priset i Erbjudandet, f\u00f6rutsatt dock att detta uttalande inte ska g\u00e4lla om ett konkurrerande erbjudande offentligg\u00f6rs. Acceptperioden f\u00f6r Erbjudandet ber\u00e4knas inledas omkring den 20 november 2026 och avslutas omkring den 18 december 2026, med f\u00f6rbeh\u00e5ll f\u00f6r eventuella f\u00f6rl\u00e4ngningar. Utbetalning av vederlag ber\u00e4knas inledas omkring den 29 december 2026.<\/p>\n<p>Fullf\u00f6ljandet av Erbjudandet \u00e4r f\u00f6rem\u00e5l f\u00f6r sedvanliga villkor, bland annat att Erbjudandet accepteras i s\u00e5dan utstr\u00e4ckning att ANI blir \u00e4gare till aktier som representerar mer \u00e4n 90 procent av det totala antalet utest\u00e5ende aktier i Egetis (efter full utsp\u00e4dning) och att samtliga erforderliga tillst\u00e5nd, godk\u00e4nnanden, beslut och andra \u00e5tg\u00e4rder fr\u00e5n myndigheter eller liknande, inklusive fr\u00e5n konkurrensmyndigheter och granskningsmyndigheter f\u00f6r utl\u00e4ndska direktinvesteringar, har erh\u00e5llits. Erbjudandet \u00e4r inte villkorat av finansiering. Se ANI:s pressmeddelande avseende Erbjudandet f\u00f6r ytterligare information.<\/p>\n<p>Styrelsen har, p\u00e5 skriftlig beg\u00e4ran av ANI, till\u00e5tit ANI att genomf\u00f6ra en sedvanlig bekr\u00e4ftande due diligence-granskning av Egetis i samband med f\u00f6rberedelserna av Erbjudandet. ANI har inte mottagit n\u00e5gon insiderinformation avseende Egetis i samband med sin due diligence-granskning, med undantag f\u00f6r viss prelimin\u00e4r finansiell information avseende Egetis resultat f\u00f6r det tredje kvartalet 2026. Denna information kommer att inkluderas i Egetis del\u00e5rsrapport f\u00f6r det tredje kvartalet 2026 som kommer att publiceras genom ett separat pressmeddelande idag.<\/p>\n<p>Frazier Life Sciences, Cidro F\u00f6rvaltning AB, Cetoros AB, Avla Holding AB, The Invus Group och RegulaPharm AB, aktie\u00e4gare i Egetis, som tillsammans representerar 196 127 092 aktier i Egetis, vilket motsvarar cirka 42,2 procent av det totala antalet utest\u00e5ende aktier i Egetis, har \u00e5tagit sig gentemot ANI att acceptera Erbjudandet, med f\u00f6rbeh\u00e5ll f\u00f6r vissa villkor, inklusive att inget konkurrerande erbjudande offentligg\u00f6rs till ett pris per aktie som \u00f6verstiger priset per aktie i Erbjudandet med mer \u00e4n fem (5) procent och som ANI inte matchar (de \u201d<strong>O\u00e5terkalleliga \u00c5tagandena<\/strong>\u201d). Se ANI:s pressmeddelande avseende Erbjudandet f\u00f6r mer information om de O\u00e5terkalleliga \u00c5tagandena.<\/p>\n<p>Centerview Partners LLC \u00e4r finansiell r\u00e5dgivare till Egetis och Advokatfirman Vinge \u00e4r legal r\u00e5dgivare till Egetis.<\/p>\n<p><strong>Styrelsens rekommendation<\/strong><br \/>Styrelsens rekommendation av Erbjudandet \u00e4r baserad p\u00e5 en utv\u00e4rdering av ett antal relevanta faktorer, inklusive, men inte begr\u00e4nsat till, Egetis nuvarande position som ett bolag i kommersiell fas inom s\u00e4llsynta sjukdomar, dess f\u00f6rv\u00e4ntade framtida utveckling och d\u00e4rtill relaterade m\u00f6jligheter och risker.<\/p>\n<p>Styrelsen anser att transaktionen inte bara skapar v\u00e4rde f\u00f6r Egetis aktie\u00e4gare, utan \u00e4ven g\u00f6r det m\u00f6jligt f\u00f6r Egetis att tillvarata ANI:s etablerade plattform inom s\u00e4llsynta sjukdomar och dess kommersialiseringsf\u00f6rm\u00e5ga i USA, i syfte att g\u00f6ra EMCITATE tillg\u00e4ngligt f\u00f6r fler patienter med MCT8-brist.<\/p>\n<p>Den f\u00f6reslagna transaktionen understryker b\u00e5da bolagens gemensamma engagemang f\u00f6r att m\u00f6ta det betydande otillfredsst\u00e4llda medicinska behovet inom s\u00e4llsynta sjukdomar genom den fortsatta globala kommersialiseringen av EMCITATE f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med monokarboxylattransport\u00f6r 8 (MCT8)-brist (Allan\u2013Herndon\u2013Dudleys syndrom), inklusive den kommersiella lanseringen i USA efter godk\u00e4nnandet fr\u00e5n den amerikanska l\u00e4kemedelsmyndigheten FDA den 28 september 2026 av EMCITATE som den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r denna indikation i USA.<\/p>\n<p>Styrelsen \u00e4r \u00f6vertygad om att ANI \u00e4r v\u00e4l positionerat f\u00f6r att accelerera den kommersiella lanseringen av EMCITATE i USA, bredda patienters tillg\u00e5ng till behandlingen och f\u00f6ra vidare Egetis viktiga uppdrag att skapa v\u00e4rde f\u00f6r patienter, samh\u00e4lle och intressenter genom att utveckla och tillhandah\u00e5lla en portf\u00f6lj av unika produkter f\u00f6r behandling av s\u00e4llsynta sjukdomar med betydande otillfredsst\u00e4llda medicinska behov.<\/p>\n<p>Vid l\u00e4mnandet av rekommendationen noterar Styrelsen att Erbjudandet \u00e4r resultatet av en konkurrensutsatt process som drivits av Egetis, med st\u00f6d av sin finansiella r\u00e5dgivare, och som f\u00f6ranleddes av att ett icke-soliciterat, icke-bindande, indikativt bud om att f\u00f6rv\u00e4rva Egetis mottogs under tredje kvartalet 2026.<\/p>\n<p>Vid utv\u00e4rderingen av Erbjudandet har Styrelsen \u00e4ven beaktat de O\u00e5terkalleliga \u00c5tagandena fr\u00e5n Egetis aktie\u00e4gare Frazier Life Sciences, Cidro F\u00f6rvaltning AB, Cetoros AB, Avla Holding AB, The Invus Group och RegulaPharm AB, vars sammanlagda aktieinnehav motsvarar cirka 42,2 procent av det totala antalet utest\u00e5ende aktier i Egetis.<\/p>\n<p>Mot bakgrund av denna utv\u00e4rdering anser Styrelsen att villkoren i Erbjudandet \u00e5terspeglar Egetis tillv\u00e4xtutsikter, liksom de risker som \u00e4r f\u00f6rknippade med dessa utsikter, inklusive kostnaderna och genomf\u00f6randerisken i en egen sj\u00e4lvst\u00e4ndig kommersiell uppbyggnad och lansering av EMCITATE i USA.<\/p>\n<p>P\u00e5 denna grund rekommenderar Styrelsen enh\u00e4lligt aktie\u00e4garna i Egetis och innehavaren av Konvertibeln och Teckningsoptionerna att acceptera Erbjudandet.<\/p>\n<p>Enligt Takeover-reglerna ska Styrelsen, p\u00e5 grundval av vad ANI har uttalat i sitt offentligg\u00f6rande av Erbjudandet, redovisa sin uppfattning om den inverkan som genomf\u00f6randet av Erbjudandet kan komma att ha p\u00e5 Egetis, s\u00e4rskilt vad g\u00e4ller syssels\u00e4ttningen, samt sin uppfattning om ANI:s strategiska planer f\u00f6r Egetis och de effekter som dessa kan f\u00f6rv\u00e4ntas f\u00e5 p\u00e5 syssels\u00e4ttningen och p\u00e5 de orter d\u00e4r Egetis bedriver sin verksamhet. ANI har i denna del uttalat f\u00f6ljande:<\/p>\n<p>\u201dANI s\u00e4tter stort v\u00e4rde p\u00e5 kompetensen och expertisen hos Egetis ledning och anst\u00e4llda och avser att forts\u00e4tta v\u00e4rna den goda relation som Egetis har med sina anst\u00e4llda. Baserat p\u00e5 ANI:s nuvarande k\u00e4nnedom om Egetis och mot bakgrund av nuvarande marknadsf\u00f6rh\u00e5llanden avser ANI inte att genomf\u00f6ra n\u00e5gra v\u00e4sentliga f\u00f6r\u00e4ndringar avseende bolagens verksamheter eller de platser d\u00e4r bolagen bedriver sina verksamheter, och inte heller n\u00e5gra v\u00e4sentliga f\u00f6r\u00e4ndringar avseende bolagens ledning och anst\u00e4llda, inklusive deras anst\u00e4llningsvillkor.\u201d<\/p>\n<p>Styrelsen har ingen anledning att ifr\u00e5gas\u00e4tta dessa uttalanden avseende syssels\u00e4ttningen, ANI:s strategiska planer f\u00f6r Egetis eller de effekter som dessa kan f\u00f6rv\u00e4ntas f\u00e5 p\u00e5 syssels\u00e4ttningen och de platser d\u00e4r Egetis bedriver sin verksamhet.<\/p>\n<p>Svensk r\u00e4tt ska i alla avseenden till\u00e4mpas p\u00e5 detta uttalande och uttalandet ska tolkas i enlighet h\u00e4rmed. Tvist i anledning av detta uttalande ska exklusivt avg\u00f6ras av svensk domstol.<\/p>\n<p style=\"text-align: center\">Stockholm den 5 november 2026<br \/>Egetis Therapeutics AB (publ)<br \/><em>Styrelsen<\/em><\/p>\n<p><strong>Om Egetis Therapeutics<\/strong><\/p>\n<p>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar med betydande otillfredsst\u00e4llda medicinska behov. Genom att kombinera vetenskaplig och klinisk expertis med integrerad kompetens inom sen klinisk utveckling, regulatoriska fr\u00e5gor och kommersialisering samt expertis inom tillverkning arbetar Egetis f\u00f6r att erbjuda behandlingar och dedikerat st\u00f6d till underf\u00f6rs\u00f6rjda patientgrupper.<\/p>\n<p>Bolagets ledande produkt, EMCITATE<sup>\u00ae<\/sup> (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA.<\/p>\n<p>Med huvudkontor i Stockholm, Sverige, och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar.<\/p>\n<p>F\u00f6r mer information, bes\u00f6k egetis.com.<\/p>\n<p><strong>F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<p>Mats Blom, styrelseordf\u00f6rande f\u00f6r Egetis Therapeutics AB (publ)<br \/>+46 (0) 761 45 70 90<br \/>mats.blom@egetis.com<\/p>\n<p><em>Denna information \u00e4r s\u00e5dan information som Egetis Therapeutics AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning och Takeover-reglerna. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 5 november 2026 kl. 07:15 CET.<\/em><\/p>\n<p>[1] Baserat p\u00e5 464 965 562 utest\u00e5ende stamaktier, exklusive 25 863 043 C-aktier som innehas av Egetis. Om inget annat anges avser h\u00e4nvisningar till utest\u00e5ende aktier i detta uttalande de 464 965 562 emitterade stamaktierna i Egetis, vilket exkluderar eventuella egna aktier som innehas av Egetis (per dagen f\u00f6r detta uttalande innehar Egetis 25 863 043 egna C-aktier).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Egetis Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2026-11-05 07:15 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/7a3ee101-71e4-49f5-a0bd-70ca45118949\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande.pdf\" rel=\"noopener\" target=\"_blank\">Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Styrelsen f\u00f6r Egetis rekommenderar enh\u00e4lligt aktie\u00e4garna i Egetis och innehavaren av Konvertibeln och Teckningsoptionerna att acceptera ANI:s offentliga uppk\u00f6pserbjudande, baserat p\u00e5 den utv\u00e4rdering som redovisas nedan.","protected":false},"template":"","class_list":["post-6550","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-ca-ma","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Styrelsen f\u00f6r Egetis rekommenderar enh\u00e4lligt aktie\u00e4garna i Egetis och innehavaren av Konvertibeln och Teckningsoptionerna att acceptera ANI:s offentliga uppk\u00f6pserbjudande, baserat p\u00e5 den utv\u00e4rdering som redovisas nedan.\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\\\/\",\"name\":\"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-05T06:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/","og_locale":"sv_SE","og_type":"article","og_title":"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande - Egetis Therapeutics","og_description":"Styrelsen f\u00f6r Egetis rekommenderar enh\u00e4lligt aktie\u00e4garna i Egetis och innehavaren av Konvertibeln och Teckningsoptionerna att acceptera ANI:s offentliga uppk\u00f6pserbjudande, baserat p\u00e5 den utv\u00e4rdering som redovisas nedan.","og_url":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"8 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/","url":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/","name":"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-05T06:15:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/uttalande-fran-egetis-therapeutics-styrelse-med-anledning-av-ani-pharmaceuticals-kontanta-offentliga-uppkopserbjudande\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Uttalande fr\u00e5n Egetis Therapeutics styrelse med anledning av ANI Pharmaceuticals kontanta offentliga uppk\u00f6pserbjudande"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6550","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6550"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6551,"date":"2026-11-05T06:15:00","date_gmt":"2026-11-05T06:15:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/"},"modified":"2026-11-05T06:15:00","modified_gmt":"2026-11-05T06:15:00","slug":"statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/","title":{"rendered":"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><em><strong>The Board of Directors of Egetis unanimously recommends that the shareholders of Egetis and the holder of the Convertible and the Warrants accept the public offer from ANI, based on the assessment outlined below.<\/strong><\/em><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>Background<\/strong><br \/>This statement is made by the Board of Directors of Egetis Therapeutics AB (publ) (\u201c<strong>Egetis<\/strong>\u201d<strong> <\/strong>or the<strong> <\/strong>\u201c<strong>Company<\/strong>\u201d) (the \u201c<strong>Board<\/strong>\u201d) pursuant to section II.19 of the Takeover Rules for Nasdaq Stockholm and Nordic Growth Market NGM (the \u201c<strong>Takeover Rules<\/strong>\u201d).<\/p>\n<p>ANI Pharmaceuticals, Inc., a U.S. corporation domiciled in Delaware, whose shares are listed on The Nasdaq Global Market under the symbol \u201cANIP\u201d in the United States (\u201c<strong>ANI<\/strong>\u201d), has today announced a public cash offer to Egetis\u2019 shareholders and to the holder of the convertible loan 2023:1 (the \u201c<strong>Convertible<\/strong>\u201d) and the warrants 2023\/2033:1 (the \u201c<strong>Warrants<\/strong>\u201d) issued by Egetis to transfer all of their shares in Egetis and the Convertible and the Warrants to ANI for a consideration of SEK 11.25 per Egetis share in cash and SEK 65,750,817 in cash for the EUR 3 million principal amount of the Convertible and SEK 6.99 in cash per Warrant (the \u201c<strong>Offer<\/strong>\u201d). The total value of the Offer amounts to approximately SEK 5,304 million.[1]<\/p>\n<p><strong>The price per share in the Offer represents a premium of:<\/strong><\/p>\n<ul>\n<li>approximately 12.6 percent compared to the closing price of SEK 9.99 of an Egetis share on Nasdaq Stockholm on 4 November 2026, which was the last day of trading prior to the announcement of the Offer;<\/li>\n<li>approximately 27.0 percent compared to the volume-weighted average trading price of SEK 8.86 of an Egetis share on Nasdaq Stockholm during the last 60 trading days prior to the announcement of the Offer; and<\/li>\n<li>approximately 48.0 percent compared to the volume-weighted average trading price of SEK 7.60 of an Egetis share on Nasdaq Stockholm during the last 180 trading days prior to the announcement of the Offer.<\/li>\n<\/ul>\n<p>ANI will not increase the price in the Offer, provided, however, that this statement shall not apply if a competing offer is announced. The acceptance period for the Offer is expected to commence on or around 20 November 2026 and expire on or around 18 December 2026, subject to any extensions. Settlement is expected to be initiated on or around 29 December 2026.<\/p>\n<p>Completion of the Offer is conditional upon customary conditions, <em>inter alia<\/em>, that the Offer is accepted to such an extent that ANI becomes the owner of shares representing more than 90 percent of the outstanding shares in Egetis (on a fully diluted basis) and that all necessary regulatory, governmental or similar clearances, approvals and decisions, including from competition and foreign direct investment authorities, are received. The Offer is not subject to any financing condition. Please refer to ANI\u2019s press release regarding the Offer for further information.<\/p>\n<p>The Board has, at the written request of ANI, permitted ANI to carry out a customary confirmatory due diligence review of Egetis in relation to the preparation of the Offer. ANI has not received any inside information relating to Egetis in connection with its due diligence review, except for certain preliminary financial information concerning Egetis\u2019 third quarter 2026 results. This information will be included in Egetis\u2019 interim report for the third quarter of 2026, which will be released through a separate press release today.<\/p>\n<p>Frazier Life Sciences, Cidro F\u00f6rvaltning AB, Cetoros AB, Avla Holding AB, The Invus Group and RegulaPharm AB, shareholders in Egetis, in aggregate representing 196,127,092 shares in Egetis, which corresponds to approximately 42.2 percent of the total number of outstanding shares in Egetis, have entered into undertakings with ANI to accept the Offer, subject to certain conditions, including that no competing offer at a price per share exceeding the price per share in the Offer by more than five (5) percent is announced which ANI does not match (the \u201c<strong>Irrevocable Undertakings<\/strong>\u201d). Please refer to ANI\u2019s press release regarding the Offer for more information about the Irrevocable Undertakings.<\/p>\n<p>Centerview Partners LLC is acting as financial advisor to Egetis and Advokatfirman Vinge is serving as legal advisor to Egetis.<\/p>\n<p><strong>The Board\u2019s recommendation<\/strong><br \/>The Board\u2019s recommendation of the Offer is based on an assessment of a number of relevant factors, including, but not limited to, Egetis\u2019 present position as a commercial-stage rare disease company, its expected future development and related opportunities and risks.<\/p>\n<p>In the Board\u2019s opinion, the transaction not only delivers value to Egetis\u2019 shareholders, but also enables Egetis to leverage ANI\u2019s established rare disease platform and commercialization capabilities in the United States, with the aim of making EMCITATE available to more patients with MCT8 deficiency.<\/p>\n<p>The proposed transaction highlights the shared commitment of both companies in addressing the substantial unmet medical need in the rare disease space, with the continued commercialization of EMCITATE globally for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan\u2013Herndon\u2013Dudley syndrome), including the commercial launch in the United States following the approval by the U.S. Food and Drug Administration on 28 September 2026 as the first and only approved treatment for this indication in the United States.<\/p>\n<p>The Board is confident that ANI is well positioned to accelerate the commercial launch of EMCITATE in the United States, broaden patient access and continue Egetis\u2019 important mission to create value for patients,\u00a0society\u00a0and stakeholders by developing and providing a portfolio of unique products for the treatment of rare diseases with substantial unmet medical\u00a0need.<\/p>\n<p>In making the recommendation, the Board notes that the Offer was the result of a competitive process run by Egetis, supported by its financial advisor, that was precipitated by the receipt of an unsolicited, non-binding indicative proposal to acquire Egetis in the third quarter of 2026.<\/p>\n<p>In its evaluation of the Offer, the Board also took into account the Irrevocable Undertakings from Egetis\u2019 shareholders Frazier Life Sciences, Cidro F\u00f6rvaltning AB, Cetoros AB, Avla Holding AB, The Invus Group and RegulaPharm AB, whose shareholdings in aggregate represent approximately 42.2 percent of the total number of outstanding shares in Egetis.<\/p>\n<p>Having concluded this assessment, the Board believes that the terms of the Offer recognize Egetis\u2019 growth prospects, as well as the risks associated with those prospects, including the costs and execution risk of a standalone U.S. commercial build-out and launch of EMCITATE.<\/p>\n<p>On this basis, the Board unanimously recommends that the shareholders of Egetis and the holder of the Convertible and the Warrants accept the Offer.<\/p>\n<p>Under the Takeover Rules, the Board is required, on the basis of ANI\u2019s statements in the announcement of the Offer, to make public its opinion of the effects the implementation of the Offer may have on Egetis, specifically employment, and its views on ANI\u2019s strategic plans for Egetis and the effect these may be expected to have on employment and the places where Egetis conducts its business. ANI has in this respect communicated:<\/p>\n<p>\u201cANI places great value on the skills and expertise of Egetis\u2019 management and employees and intends to continue to safeguard the excellent relationship that Egetis has with its employees. Based on ANI\u2019s current knowledge of Egetis and in light of current market conditions, ANI does not intend to make any material changes to the companies\u2019 operations or to the locations where the companies conduct their business, nor any material changes with respect to the companies\u2019 management and employees, including their terms of employment.\u201d<\/p>\n<p>The Board has no reason to question these statements regarding employment, ANI\u2019s strategic plans for Egetis or the impact these could be expected to have on employment and on Egetis\u2019 business locations.<\/p>\n<p>This statement shall in all respects be governed by and construed in accordance with Swedish law. Any dispute arising out of or in connection with this statement shall be settled exclusively by Swedish courts.<\/p>\n<p style=\"text-align: center\">Stockholm on 5 November 2026<br \/>Egetis Therapeutics AB (publ)<br \/><em>The Board of Directors<\/em><\/p>\n<p><strong>About Egetis Therapeutics<\/strong><\/p>\n<p>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.<\/p>\n<p>The Company\u2019s lead product, EMCITATE<sup>\u00ae<\/sup> (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.<\/p>\n<p>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<\/p>\n<p>For more information, visit egetis.com.<\/p>\n<p><strong>For further information, please contact:<\/strong><\/p>\n<p>Mats Blom, Chairman of the Board of Directors at Egetis Therapeutics AB (publ)<br \/>+46 (0) 761 45 70 90<br \/>mats.blom@egetis.com<\/p>\n<p><em>This information is information that Egetis Therapeutics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Takeover Rules. The information was submitted for publication, through the agency of the contact person set out above, on 5 November<\/em> 2026<em>, at 07:15 CET.<\/em><\/p>\n<p>[1] Based on 464,965,562 ordinary shares outstanding, excluding 25,863,043 Class C shares held by Egetis. Unless otherwise stated, references to outstanding shares in this statement refer to the 464,965,562 issued ordinary shares in Egetis, which excludes any treasury shares held by Egetis (as of the date of this statement Egetis holds 25,863,043 Class C shares in treasury).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-05 07:15 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/fc65b2c1-52c7-478a-a15d-1f826f4251d3\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals.pdf\" rel=\"noopener\" target=\"_blank\">Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"The Board of Directors of Egetis unanimously recommends that the shareholders of Egetis and the holder of the Convertible and the Warrants accept the public offer from ANI, based on the assessment outlined below.","protected":false},"template":"","class_list":["post-6551","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-ca-ma","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-regulatory"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"The Board of Directors of Egetis unanimously recommends that the shareholders of Egetis and the holder of the Convertible and the Warrants accept the public offer from ANI, based on the assessment outlined below.\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\\\/\",\"name\":\"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-05T06:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/","og_locale":"sv_SE","og_type":"article","og_title":"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals - Egetis Therapeutics","og_description":"The Board of Directors of Egetis unanimously recommends that the shareholders of Egetis and the holder of the Convertible and the Warrants accept the public offer from ANI, based on the assessment outlined below.","og_url":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"8 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/","url":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/","name":"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-05T06:15:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/statement-by-the-board-of-directors-of-egetis-therapeutics-in-relation-to-the-public-cash-offer-from-ani-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Statement by the Board of Directors of Egetis Therapeutics in relation to the public cash offer from ANI Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6551","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6551"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6530,"date":"2026-11-04T07:32:00","date_gmt":"2026-11-04T07:32:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/"},"modified":"2026-11-04T07:32:00","modified_gmt":"2026-11-04T07:32:00","slug":"egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","title":{"rendered":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm den 4 november 2026. <\/strong>\u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka 1 900 miljoner SEK) f\u00f6re avdrag, vilken kommer att erh\u00e5llas i samband med att transaktionen slutf\u00f6rs. Tidigare \u00e4gare av RTTI har r\u00e4tt till cirka 50 procent av nettoint\u00e4kterna fr\u00e5n PRV:n i form av en till\u00e4ggsk\u00f6peskilling efter Egetis f\u00f6rv\u00e4rv av EMCITATE<sup>\u00ae<\/sup> (tiratricol) 2020.<\/p>\n<p>Egetis tilldelades PRV:n den 28 september 2026 i samband med att den amerikanska l\u00e4kemedelsmyndigheten FDA godk\u00e4nde EMCITATE f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med monokarboxylattransport\u00f6r 8 (MCT8) brist.<\/p>\n<p>Transaktionen \u00e4r f\u00f6rem\u00e5l f\u00f6r sedvanliga villkor f\u00f6r slutf\u00f6rande, inklusive att den till\u00e4mpliga v\u00e4ntetiden enligt den amerikanska Hart-Scott-Rodino (HSR) Antitrust Improvements Act l\u00f6per ut.<\/p>\n<p><strong>Om Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov.<br \/>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos patienter med MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom. EMCITATE har marknadsgodk\u00e4nnande i EU och i USA.<br \/>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar. F\u00f6r mer information, bes\u00f6k www.egetis.com och f\u00f6lj Bolaget p\u00e5 LinkedIn.<\/p>\n<p><strong>Fram\u00e5tblickande uttalanden<\/strong><br \/>Detta pressmeddelande inneh\u00e5ller fram\u00e5tblickande uttalanden i den mening som avses i till\u00e4mplig v\u00e4rdepapperslagstiftning, inklusive uttalanden avseende kommersialiseringen och tillg\u00e4ngligheten av Emcitate\u00ae (tiratricol) i USA, tidpunkten f\u00f6r och utfallet av en eventuell monetisering av Priority Review Voucher f\u00f6r s\u00e4llsynta pediatriska sjukdomar (Rare Pediatric Disease Priority Review Voucher), den f\u00f6rv\u00e4ntade kapaciteten i Bolagets infrastruktur f\u00f6r patient\u00e5tkomst och distribution, de f\u00f6rv\u00e4ntade f\u00f6rdelarna med Emcitate f\u00f6r patienter med MCT8-brist samt Bolagets \u00f6vergripande strategiska planer f\u00f6r utveckling och kommersialisering av behandlingar f\u00f6r s\u00e4llsynta sjukdomar. Fram\u00e5tblickande uttalanden kan i allm\u00e4nhet identifieras genom ord s\u00e5som \u201df\u00f6rv\u00e4ntar\u201d, \u201dbed\u00f6mer\u201d, \u201davser\u201d, \u201danser\u201d, \u201duppskattar\u201d, \u201dplanerar\u201d, \u201dkommer att\u201d, \u201dkan\u201d, \u201dskulle kunna\u201d, \u201dpotentiell\u201d eller liknande uttryck, \u00e4ven om inte alla fram\u00e5tblickande uttalanden inneh\u00e5ller s\u00e5dana ord.<br \/>Dessa uttalanden baseras p\u00e5 Bolagets nuvarande f\u00f6rv\u00e4ntningar, antaganden och bed\u00f6mningar per dagen f\u00f6r detta pressmeddelande och \u00e4r f\u00f6rem\u00e5l f\u00f6r risker, os\u00e4kerhetsfaktorer och andra omst\u00e4ndigheter som kan medf\u00f6ra att faktiska resultat avviker v\u00e4sentligt fr\u00e5n dem som uttryckligen eller underf\u00f6rst\u00e5tt anges i uttalandena. S\u00e5dana faktorer omfattar, men \u00e4r inte begr\u00e4nsade till, risker relaterade till den kommersiella lanseringen av och marknadsacceptansen f\u00f6r Emcitate i USA, Bolagets f\u00f6rm\u00e5ga att etablera och uppr\u00e4tth\u00e5lla en \u00e4ndam\u00e5lsenlig kommersiell infrastruktur, inklusive distributions-, patientst\u00f6ds- och ers\u00e4ttningsl\u00f6sningar, tidpunkten f\u00f6r och villkoren f\u00f6r en eventuell monetisering av Priority Review Voucher, vilken \u00e4r beroende av marknadsf\u00f6rh\u00e5llanden och tillg\u00e5ngen p\u00e5 intresserade k\u00f6pare, eventuella krav eller begr\u00e4nsningar efter marknadsgodk\u00e4nnande som kan komma att inf\u00f6ras av den amerikanska l\u00e4kemedelsmyndigheten FDA, Bolagets f\u00f6rm\u00e5ga att uppr\u00e4tth\u00e5lla regulatoriska godk\u00e4nnanden i USA och Europeiska unionen, konkurrens fr\u00e5n befintliga eller framtida behandlingar, Bolagets m\u00f6jlighet att s\u00e4kerst\u00e4lla tillr\u00e4cklig finansiering f\u00f6r sin verksamhet och sina kommersiella aktiviteter samt allm\u00e4nna ekonomiska, marknadsm\u00e4ssiga och aff\u00e4rsm\u00e4ssiga f\u00f6rh\u00e5llanden.<br \/>F\u00f6r en n\u00e4rmare beskrivning av risker och os\u00e4kerhetsfaktorer som kan p\u00e5verka Bolagets verksamhet och resultat h\u00e4nvisas till Bolagets senaste \u00e5rsredovisning samt \u00f6vriga handlingar som getts in till relevanta tillsynsmyndigheter och som finns tillg\u00e4ngliga p\u00e5 <a href=\"http:\/\/www.egetis.com.\/\" rel=\"noopener\" target=\"_blank\">www.egetis.com.<\/a><br \/>Bolaget \u00e5tar sig inte n\u00e5gon skyldighet att offentligt uppdatera eller revidera fram\u00e5tblickande uttalanden, vare sig till f\u00f6ljd av ny information, framtida h\u00e4ndelser eller av andra sk\u00e4l, annat \u00e4n vad som f\u00f6ljer av till\u00e4mplig lag eller regelverk.<\/p>\n<p><strong>F\u00f6r mer information, v\u00e4nligen kontakta<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/><a href=\"mailto:nicklas.westerholm@egetis.com\" rel=\"noopener\" target=\"_blank\">nicklas.westerholm@egetis.com<\/a><\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications & Business Development<br \/>+46 (0) 733 011 944<br \/><a href=\"mailto:karl.hard@egetis.com\" rel=\"noopener\" target=\"_blank\">karl.hard@egetis.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Egetis Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2026-11-04 08:32 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/fa4c6190-01e7-4f05-a554-daf661b72574\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm den 4 november 2026. \u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka […]","protected":false},"template":"","class_list":["post-6530","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-ca-other","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm den 4 november 2026. \u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/\",\"name\":\"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-04T07:32:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics","og_description":"Stockholm den 4 november 2026. \u2013 Egetis Therapeutics AB (publ) (\u201dEgetis\u201d eller \u201dBolaget\u201d) (Nasdaq Stockholm: EGTX) meddelar idag att Bolaget, tillsammans med det hel\u00e4gda dotterbolaget Rare Thyroid Therapeutics International AB (RTTI), har ing\u00e5tt ett slutligt avtal om f\u00f6rs\u00e4ljning av sin Rare Pediatric Disease Priority Review Voucher (PRV) f\u00f6r en k\u00f6peskilling om 190 miljoner USD (cirka […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"4 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/","name":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-04T07:32:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-ingar-avtal-om-forsaljning-av-priority-review-voucher-for-190-miljoner-usd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics ing\u00e5r avtal om f\u00f6rs\u00e4ljning av Priority Review Voucher f\u00f6r 190 miljoner USD"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6531,"date":"2026-11-04T07:32:00","date_gmt":"2026-11-04T07:32:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/"},"modified":"2026-11-04T07:32:00","modified_gmt":"2026-11-04T07:32:00","slug":"egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","title":{"rendered":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm, Sweden, November 4, 2026. <\/strong>\u2013 Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 190 million (approximately SEK 1,900 million). Upon the closing of the transaction former owners of RTTI are entitled to approximately 50 percent of net proceeds of the PRV, as an earnout following Egetis\u2019 acquisition of EMCITATE<sup>\u00ae<\/sup> (tiratricol) in 2020.<\/p>\n<p>Egetis was granted the PRV on September 28, 2026, in connection with the U.S. Food and Drug Administration (FDA) approval of EMCITATE for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency.<\/p>\n<p>The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act.<\/p>\n<p><strong>About Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need.<\/p>\n<p>Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities, and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company's lead product, EMCITATE<sup>\u00ae<\/sup> (tiratricol), is the first and only approved treatment of peripheral thyrotoxicosis in patients with MCT8 deficiency, a rare and life-shortening genetic disorder. EMCITATE holds marketing authorizations in the EU and in the U.S. \u00a0<\/p>\n<p>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<\/p>\n<p>For more information, visit egetis.com and follow the Company on LinkedIn.<\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE\u00ae (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company\u2019s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company\u2019s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions, although not all forward-looking statements contain these words.<\/p>\n<p>These statements are based on the Company\u2019s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company\u2019s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions.<\/p>\n<p>For a further description of risks and uncertainties that could affect the Company\u2019s business and results, reference is made to the Company\u2019s most recent annual report and other filings with relevant regulatory authorities available at www.egetis.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.<\/p>\n<p><strong>Investor contacts<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/>nicklas.westerholm@egetis.com<\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications & Business Development<br \/>+46 (0) 733 011 944<br \/>karl.hard@egetis.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>This information is information that Egetis Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-11-04 08:32 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/369a492f-5574-4d17-b392-ad12628a3711\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, Sweden, November 4, 2026. \u2013 Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of […]","protected":false},"template":"","class_list":["post-6531","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn","mfn-news-tag-mfn-ca-other","mfn-news-tag-mfn-regulatory"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, Sweden, November 4, 2026. \u2013 Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/\",\"name\":\"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-11-04T07:32:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics","og_description":"Stockholm, Sweden, November 4, 2026. \u2013 Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), today announced that the Company, together with its wholly-owned subsidiary Rare Thyroid Therapeutics International AB (RTTI), has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","og_site_name":"Egetis Therapeutics","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/","name":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-11-04T07:32:00+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-enters-agreement-to-sell-priority-review-voucher-for-usd-190-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics Enters Agreement to Sell Priority Review Voucher for USD 190 Million"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6531","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6531"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6518,"date":"2026-10-27T13:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/"},"modified":"2026-10-27T13:23:35","modified_gmt":"2026-10-27T13:23:35","slug":"egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","title":{"rendered":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency"},"content":{"rendered":"<div class=\"mfn-body\">\n<ul>\n<li><strong>EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States<\/strong><strong><br \/><\/strong><\/li>\n<li><strong>Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy<\/strong><\/li>\n<\/ul>\n<p><strong>Stockholm, Sweden, October 27, 2026 <\/strong>\u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or the \u201cCompany\u201d) (Nasdaq Stockholm: EGTX), a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases, today announced the commercial availability of EMCITATE<strong>\u00ae<\/strong> (tiratricol), ahead of anticipated timelines following U.S. Food and Drug Administration (FDA) approval on September 28, 2026.<\/p>\n<p>EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome. It is the first and only FDA-approved treatment for MCT8 deficiency in the United States. EMCITATE is not recommended for the treatment of primary hypothyroidism.<\/p>\n<p><em>\u201cLaunching EMCITATE in the United States ahead of our anticipated timelines marks an important milestone for people living with MCT8 deficiency, their families and everyone who has worked toward bringing an approved treatment to this community,\u201d<\/em> <strong>said Nicklas Westerholm, chief executive officer of Egetis Therapeutics.<\/strong> <em>\u201cFollowing FDA approval, our focus is now on building on this momentum and helping eligible patients access treatment as quickly as possible. We remain deeply committed to the MCT8 deficiency community and grateful to the patients, families, clinicians, investigators and advocacy organizations that continue to support these efforts.\u201d<\/em><\/p>\n<p>MCT8 deficiency is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the <em>SLC16A2<\/em> gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. The resulting disruption of thyroid hormone signaling leads to severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.<\/p>\n<p>To support the U.S. launch, Egetis has established Egetis RareLink, its dedicated patient support program, in partnership with PANTHERx Rare Pharmacy. The program is designed to help eligible patients, caregivers and health care professionals navigate medication access, education, care coordination and ongoing treatment services.<\/p>\n<p>Through Egetis RareLink, the Company aims to provide dedicated support and help eligible patients access EMCITATE. Patients and caregivers can learn more by calling 1-844-4EGETIS (1-844-434-3847) or go to <a href=\"https:\/\/www.emcitate.com\/\" rel=\"noopener\" target=\"_blank\">EMCITATE.com<\/a>.<\/p>\n<p><strong>About EMCITATE\u00ae<\/strong><br \/>EMCITATE (tiratricol) is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan\u2013Herndon\u2013Dudley syndrome).<\/p>\n<p><strong>Limitation of use:<\/strong> EMCITATE is not recommended for the treatment of primary hypothyroidism.<\/p>\n<p><strong>About MCT8 Deficiency<\/strong><br \/>Monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan\u2013Herndon\u2013Dudley syndrome (AHDS), is a rare, devastating, life-limiting, X-linked disorder caused by pathogenic mutations in the <em>SLC16A2<\/em> gene. These mutations impair the function of MCT8, a critical cell-surface thyroid hormone transporter responsible for thyroid hormone transport in specific cells, including in the brain. Patients experience insufficient thyroid hormone activity in the central nervous system and excessive exposure to the active thyroid hormone triiodothyronine (T3) in peripheral tissues. This results in severe neurodevelopmental impairment and persistent peripheral thyrotoxicosis.<\/p>\n<p>Elevated T3 concentrations in peripheral tissues can result in a chronic hypermetabolic state affecting multiple organs, including the heart, muscles, liver and kidneys. Clinical manifestations may include failure to thrive, cardiovascular strain, muscle wasting, metabolic imbalance and increased susceptibility to infections. These systemic consequences are believed to contribute significantly to the increased morbidity and premature mortality associated with the disorder. Patients with MCT8 deficiency have a reported median life expectancy of approximately 35 years.<\/p>\n<p>For more information about MCT8 deficiency, visit <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DMCT8deficiency.com%26t%3Dh.eJxFjckKwjAURX-lZC2Jbaamq4Jrd_5AhhcbTAdCKgbx3yWouD33cO4T7SmioUFTzttAyPl06R34YAMstmC7zujQoFs17mDzmgqJAHpZ8LynbSrjl-ZHdYnhYJyQVEvGQRjqNG3BcuWplxqYIq1UHRNH2nMsBGtFp2ofaj_qT5KP11mH-Pt2dfuT1xv11jdB.MEUCIHg6doYCMEJhuKWMRFNHea5t4YAgM27qqNGISfcltg-DAiEAhom4KGuOBYCj0drrBTpmG36Msl-cLGPqTkMRh1eEM7w&data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207498216|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=qdmkmjnaW5msUzXvptCQOxpt8yrRY3yGGD%2F7KkITvF8%3D&reserved=0\" rel=\"noopener\" target=\"_blank\">MCT8deficiency.com<\/a> or <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DLifewithMCT8deficiency.com%26t%3Dh.eJxFjU0OwiAYBa_SsDbFlr_SVRO3uvMCFD4sEdqGUJUY726IGrfzJvOeaIse9RWaUlp7jI_Owt2l6XQ4dwas0w5mnWu9BLSr0LWYN9BpiRl7ADXPddjiOuXhS9OjuHhkMBouiBKUAR-JUaQBzaQlViigEjdCtpTvScdqzmnDW1n6UPpefZJsuATl_O_blO1PXm83Njp9.MEUCIQDA6ds0KCxxhOUSX7LGs-kFQey3hg3Ptclc34eJgEnVzAIgfJ6qbFF1u6RMx5WlpmB_46aeWQPcOLMs0wSoTED6Gq0&data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207523131|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=g3IqD53R53SytRGIfA1bZND8umdRmOJFgLeKBXVvISQ%3D&reserved=0\" rel=\"noopener\" target=\"_blank\">LifewithMCT8deficiency.com<\/a>.<\/p>\n<p><strong>Important Safety Information<\/strong><br \/><strong>BOXED WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS<\/strong><\/p>\n<p><strong>Contraindications:<\/strong> EMCITATE is contraindicated in patients with primary hyperthyroidism.<\/p>\n<p><strong>Warnings and precautions<\/strong><\/p>\n<ul>\n<li><strong>Thyrotoxicosis:<\/strong> Signs and symptoms of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia and nightmares, have occurred during treatment initiation and dose titration. Monitor patients and adjust the EMCITATE dose as indicated.<\/li>\n<li><strong>Laboratory test interference for T3 measurement:<\/strong> Tiratricol can cross-react with immunoassays for T3, leading to unreliable T3 results and overestimation of T3.<\/li>\n<\/ul>\n<p><strong>Adverse reactions:<\/strong> The most common adverse reactions (\u22655%) are diarrhea, vomiting, rash and hyperhidrosis. To report suspected adverse reactions, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or the FDA at 1-800-FDA-1088 or<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.fda.gov%26t%3Dh.eJxFzEsOgyAUheGtGMYNVHkVR27lChdpCmoMSk3TvTekTTo9_8n3IvsWSd-QkPPaM1ZKod4BnZaDJXQFsg3k0pBH_Rxo87KdLCLCPNO0b2s4h9-an9QuiY0SR6c0By0kqpE74C1aaTz3GlAY1mrTCXXlN0mVEq3qTPWx-hG-pBymBPdYvdpcbf_l_QGxgzhZ.MEUCIGwmDLgOpbTorJpKGnqkhEC08vn9CYT2zKuYs1CAJ34tAiEA0P_Ca3ZdskwDJjHtAeKrqA1_BJsXMHgebYmBSEbyW5Y&data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207547606|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=tZ%2ByoYo0HXT0SMF9vcb1ifgONUb6a3h8Q6p6oxj%2Fe8o%3D&reserved=0\" rel=\"noopener\" target=\"_blank\"> www.fda.gov\/medwatch<\/a>.<\/p>\n<p><strong>Please see the full Prescribing Information:<\/strong><a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.egetis.com%26t%3Dh.eJxFzduOwiAUheFXMVxPYSqFTr3yVXZhU8lwCt21Yya-u0FNvP1X8q1_ttXATgd2ISrrSYh93zkuSH7lJkexl87kRJhIbCVksKvAaDwBYee2ELpScTXVzz4tnU8u1wjkc-LFOvZ1YL_NvqKhXG8iIEJKPG61XG7nd6W_59GscLZ6lDAOCvUsLcgejZqcdCPgMIl-nI6D_pY_ims99Po4NR-bH-BFqvMSwYfmtc227VPuD0rFTlk.MEQCIC_USug_zF2pxnijA76can_m8hy5uKqPlEVeGhwdcn96AiBa-iLK80TlSh3VCbbpLLKexX0cTp_2AE4Db63spOhogQ&data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207571099|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=KPbzcRri95K8lJflYYHUD8Xm96OhlLvcaBQGTxU%2B3f0%3D&reserved=0\" rel=\"noopener\" target=\"_blank\"> https:\/\/www.egetis.com\/wp-content\/uploads\/emcitate-full-prescribing-information.pdf<\/a><\/p>\n<p><strong>About Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need.<\/p>\n<p>Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities, and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities. The Company\u2019s lead product, EMCITATE\u00ae (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and the United States.<\/p>\n<p>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<\/p>\n<p>For more information, visit <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Degetis.com%26t%3Dh.eJxFjcsOwiAUBX-lYW1AClykq_4Kj9tHhLZBamyM_26IGrczJ3OeZM-RdA2ZStk6xnDEMt-oXxM5NeRazR19WfPBIqJdFpr2vE1H_6XlUbfMKXQBtLBaKgQnghUcvTKDGLRFaRjXppVwFhdFASSH1tQ-1n60n6Tqx2Tn-PsO1f3J6w0mmDST.MEQCIB4JZGYoog_uRKzv5LdNwb6ReHfGz_FTn5pTGzbeXG41AiA-rJrIwGw6DwwUWrZG0hy73aB7TG7Q0nP6Co0lbx77zw&data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207594861|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=rUnWIy9VP1hKEiCssBtJrCLYGiGfWiMj0oII%2FvS7xHs%3D&reserved=0\" rel=\"noopener\" target=\"_blank\">egetis.com<\/a> and follow the Company on LinkedIn.<\/p>\n<p><strong>About PANTHERx Rare<\/strong><br \/>PANTHERx Rare makes rare disease care more personalized and less overwhelming by focusing on each patient and each therapy. PANTHERx experts develop relationships with patients, prescribers and pharmaceutical partners, serving as trusted advocates to support collaboration and care. Founded in Pittsburgh, Pennsylvania, in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S. PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual rare disease accreditations from the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). PANTHERx received the 2026 MMIT Patient Choice Award for patient satisfaction, marking its ninth win.<\/p>\n<p>For more information, visit<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.pantherxrare.com%26t%3Dh.eJxFjEsOwiAUAK_SsDYg5Sdd9Sqv8GqNlBJCbRvj3Q1q4nZmMk-y5kC6hkylpI6xbdtoglgmzHuGjNQtMyOnhtxr9EBXlnywgAgx0nnNaTr6Hy37Jx4UDl4bAUYq1IPwIDg6ZUcxGkBpGTe2lfosLopqLblubf1j_Qf4LlV_neEW6q86X92fvN4VDjjo.MEUCIB0HNNLiS7VhlxPx0j-xv2y3og9--PvO1KslZpSLB1K1AiEA0KwPOY7Oz-K6P8IUosuZbFb7x4TW1Ncqq5McauJUbjU&data=05|02|leeann.murphy%40vectorytx.com|749eb81b26b34499c81708df2e4b0656|48c522b05e5d4e2184f06ff6ad85c432|0|0|639280572207618223|Unknown|TWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D|0|||&sdata=bsKhLCi1D32XdwxUNPjvUW52z7WPtdo9lzVjUhI0S3I%3D&reserved=0\" rel=\"noopener\" target=\"_blank\"> www.pantherxrare.com<\/a>.<\/p>\n<p><strong>For further information, please contact:<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/><a href=\"mailto:nicklas.westerholm@egetis.com\" rel=\"noopener\" target=\"_blank\">nicklas.westerholm@egetis.com<\/a><\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications & Business Development<br \/>+46 (0) 733 011 944<br \/><a href=\"mailto:karl.hard@egetis.com\" rel=\"noopener\" target=\"_blank\">karl.hard@egetis.com<\/a><\/p>\n<p><strong>Forward-Looking Statements<\/strong><br \/>This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the commercialization and availability of EMCITATE\u00ae (tiratricol) in the United States, the timing and outcome of potential monetization of the Rare Pediatric Disease Priority Review Voucher, the expected capabilities of the Company\u2019s patient access and distribution infrastructure, the anticipated benefits of EMCITATE for patients with MCT8 deficiency, and the Company\u2019s broader strategic plans for the development and commercialization of therapies for rare diseases. Forward-looking statements can generally be identified by words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions, although not all forward-looking statements contain these words.<br \/>These statements are based on the Company\u2019s current expectations, assumptions, and assessments as of the date of this press release and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied. Such factors include, but are not limited to: risks related to the commercial launch and market acceptance of EMCITATE in the United States; the ability to establish and maintain adequate commercial infrastructure, including distribution, patient support, and reimbursement arrangements; the timing and terms of any monetization of the Priority Review Voucher, which is subject to market conditions and the availability of interested purchasers; potential post-marketing requirements or restrictions imposed by the FDA; the ability to maintain regulatory approvals in the United States and the European Union; competition from existing or future therapies; the Company\u2019s ability to secure adequate funding for its operations and commercial activities; and general economic, market, and business conditions.<br \/>For a further description of risks and uncertainties that could affect the Company\u2019s business and results, reference is made to the Company\u2019s most recent annual report and other filings with relevant regulatory authorities available at\u00a0<a href=\"http:\/\/www.egetis.com\/\" rel=\"noopener\" target=\"_blank\">www.egetis.com<\/a>. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law or regulation.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/21d74a82-5e26-4e75-9ece-d55d0d5b55f9\/egetis-therapeutics-announces-u-s-launch-of-emcitate-r-for-patients-with-mct8-deficiency.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy Stockholm, Sweden, October 27, 2026 \u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or […]","protected":false},"template":"","class_list":["post-6518","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy Stockholm, Sweden, October 27, 2026 \u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:35+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/\",\"name\":\"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-27T13:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics","og_description":"EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink\u2122, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx\u00ae Rare Pharmacy Stockholm, Sweden, October 27, 2026 \u2013 Egetis Therapeutics AB (publ) (\u201cEgetis\u201d or […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:35+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"7 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/","name":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-27T13:00:00+00:00","dateModified":"2026-10-27T13:23:35+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics Announces U.S. Launch of EMCITATE\u00ae for Patients with MCT8 Deficiency"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6519,"date":"2026-10-27T13:00:00","date_gmt":"2026-10-27T13:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","title":{"rendered":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist"},"content":{"rendered":"<div class=\"mfn-body\">\n<ul>\n<li><strong>EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA<\/strong><strong><br \/><\/strong><\/li>\n<li><strong>Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy<\/strong><\/li>\n<\/ul>\n<p><strong>Stockholm den 27 oktober 2026 <\/strong>\u2013 Egetis Therapeutics AB (publ) ("Egetis" eller "Bolaget") (Nasdaq Stockholm: EGTX), ett kommersiellt l\u00e4kemedelsbolag med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar, meddelade idag att EMCITATE\u00ae (tiratricol) nu \u00e4r kommersiellt tillg\u00e4ngligt i USA, tidigare \u00e4n f\u00f6rv\u00e4ntat efter godk\u00e4nnandet fr\u00e5n den amerikanska l\u00e4kemedelsmyndigheten FDA (US Food and Drug Administration) den 28 september 2026.<\/p>\n<p>EMCITATE \u00e4r godk\u00e4nt f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist, \u00e4ven k\u00e4nd som Allan-Herndon-Dudleys syndrom. Det \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r MCT8-brist i USA. EMCITATE rekommenderas inte f\u00f6r behandling av prim\u00e4r hypotyreos.<\/p>\n<p><em>\u201dAtt lansera EMCITATE i USA tidigare \u00e4n v\u00e5r tidplan markerar en viktig milstolpe f\u00f6r personer som lever med MCT8-brist, deras familjer och alla som har arbetat f\u00f6r att g\u00f6ra en godk\u00e4nd behandling tillg\u00e4nglig f\u00f6r denna patientgrupp\u201d,<\/em> <strong>s\u00e4ger Nicklas Westerholm, vd f\u00f6r Egetis Therapeutics.<\/strong> <em>\u201dEfter FDA-godk\u00e4nnandet fokuserar vi nu p\u00e5 att bygga vidare p\u00e5 detta momentum och hj\u00e4lpa patienter att f\u00e5 tillg\u00e5ng till behandling s\u00e5 snabbt som m\u00f6jligt. Vi \u00e4r fortsatt djupt engagerade i dem som lider av MCT8-brist och tacksamma f\u00f6r det st\u00f6d vi f\u00e5r fr\u00e5n patienter, familjer, kliniker, pr\u00f6vare och patientorganisationer\u201d.<\/em><\/p>\n<p>MCT8-brist \u00e4r en s\u00e4llsynt, allvarlig, livsbegr\u00e4nsande, X-kromosombunden sjukdom som orsakas av sjukdomsframkallande mutationer i SLC16A2-genen. Dessa mutationer f\u00f6rs\u00e4mrar funktionen hos MCT8, ett viktigt transportprotein p\u00e5 cellmembranet som ansvarar f\u00f6r transport av sk\u00f6ldk\u00f6rtelhormon i vissa celler, inklusive i hj\u00e4rnan. Den st\u00f6rda signaleringen av sk\u00f6ldk\u00f6rtelhormon leder till sv\u00e5r neurologisk funktionsneds\u00e4ttning och ih\u00e5llande perifer tyreotoxikos. Patienter med MCT8-brist har en rapporterad medianlivsl\u00e4ngd p\u00e5 cirka 35 \u00e5r.<\/p>\n<p>Som st\u00f6d f\u00f6r lanseringen i USA har Egetis etablerat Egetis RareLink, bolagets dedikerade patientst\u00f6dsprogram, i samarbete med PANTHERx Rare Pharmacy. Programmet \u00e4r utformat f\u00f6r att hj\u00e4lpa ber\u00e4ttigade patienter, v\u00e5rdgivare och h\u00e4lso- och sjukv\u00e5rdspersonal att navigera fr\u00e5gor kring l\u00e4kemedelstillg\u00e5ng, utbildning, v\u00e5rdkoordinering och l\u00f6pande behandlingsst\u00f6d.<\/p>\n<p>Genom Egetis RareLink avser Bolaget att erbjuda personligt st\u00f6d och hj\u00e4lpa ber\u00e4ttigade patienter att f\u00e5 tillg\u00e5ng till EMCITATE\u00ae. Patienter och v\u00e5rdgivare kan f\u00e5 mer information genom att ringa 1\u2011844\u20114EGETIS (1\u2011844\u2011434\u20113847) eller bes\u00f6ka <a href=\"https:\/\/www.emcitate.com\/\" rel=\"noopener\" target=\"_blank\">EMCITATE.com.<\/a><\/p>\n<p><strong>Om EMCITATE\u00ae<\/strong><br \/>EMCITATE (tiratricol) \u00e4r en agonist till sk\u00f6ldk\u00f6rtelhormonreceptorn och \u00e4r godk\u00e4nd f\u00f6r behandling av perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist, \u00e4ven kallad Allan\u2013Herndon\u2013Dudleys syndrom.<\/p>\n<p><strong>Om MCT8-brist<\/strong><strong><br \/><\/strong>MCT8-brist, \u00e4ven k\u00e4nd som Allan-Herndon-Dudleys syndrom (AHDS), \u00e4r en s\u00e4llsynt, allvarlig och livsf\u00f6rkortande X-kromosombunden sjukdom som orsakas av sjukdomsframkallande mutationer i SLC16A2-genen. Dessa mutationer f\u00f6rs\u00e4mrar funktionen hos MCT8, en viktig transport\u00f6r p\u00e5 cellernas yta som ansvarar f\u00f6r transport av sk\u00f6ldk\u00f6rtelhormon i vissa celler, inklusive i hj\u00e4rnan. Som en f\u00f6ljd av detta f\u00e5r patienterna en st\u00f6rd signalering av sk\u00f6ldk\u00f6rtelhormon, k\u00e4nnetecknad av otillr\u00e4cklig aktivitet av sk\u00f6ldk\u00f6rtelhormon i det centrala nervsystemet och \u00f6verexponering f\u00f6r det aktiva sk\u00f6ldk\u00f6rtelhormonet trijodtyronin (T3) i perifera v\u00e4vnader. Detta leder till en komplex sjukdomsbild som pr\u00e4glas av sv\u00e5r neurologisk utvecklingsst\u00f6rning och kvarst\u00e5ende perifer tyreotoxikos.<\/p>\n<p>De f\u00f6rh\u00f6jda T3-niv\u00e5erna i perifera v\u00e4vnader kan orsaka ett kroniskt hypermetaboliskt tillst\u00e5nd som p\u00e5verkar flera organ, inklusive hj\u00e4rta, muskler, lever och njurar. Kliniska manifestationer kan omfatta otillr\u00e4cklig tillv\u00e4xt, kardiovaskul\u00e4r belastning, muskelf\u00f6rtvining, metabol obalans samt \u00f6kad mottaglighet f\u00f6r infektioner. Dessa systemiska konsekvenser av ih\u00e5llande tyreotoxikos anses bidra v\u00e4sentligt till den \u00f6kade sjukligheten och den f\u00f6rkortade livsl\u00e4ngden som \u00e4r f\u00f6rknippad med sjukdomen. Patienter med MCT8-brist har en rapporterad medianlivsl\u00e4ngd p\u00e5 cirka 35 \u00e5r.<br \/>F\u00f6r mer information om MCT8-brist, bes\u00f6k \u00a0<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DMCT8deficiency.com%26t%3Dh.eJxFjckKwjAURX-lZC2Jbaamq4Jrd_5AhhcbTAdCKgbx3yWouD33cO4T7SmioUFTzttAyPl06R34YAMstmC7zujQoFs17mDzmgqJAHpZ8LynbSrjl-ZHdYnhYJyQVEvGQRjqNG3BcuWplxqYIq1UHRNH2nMsBGtFp2ofaj_qT5KP11mH-Pt2dfuT1xv11jdB.MEUCIHg6doYCMEJhuKWMRFNHea5t4YAgM27qqNGISfcltg-DAiEAhom4KGuOBYCj0drrBTpmG36Msl-cLGPqTkMRh1eEM7w&data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207498216%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qdmkmjnaW5msUzXvptCQOxpt8yrRY3yGGD%2F7KkITvF8%3D&reserved=0\" rel=\"noopener\" target=\"_blank\">MCT8deficiency.com<\/a> eller <a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3DLifewithMCT8deficiency.com%26t%3Dh.eJxFjU0OwiAYBa_SsDbFlr_SVRO3uvMCFD4sEdqGUJUY726IGrfzJvOeaIse9RWaUlp7jI_Owt2l6XQ4dwas0w5mnWu9BLSr0LWYN9BpiRl7ADXPddjiOuXhS9OjuHhkMBouiBKUAR-JUaQBzaQlViigEjdCtpTvScdqzmnDW1n6UPpefZJsuATl_O_blO1PXm83Njp9.MEUCIQDA6ds0KCxxhOUSX7LGs-kFQey3hg3Ptclc34eJgEnVzAIgfJ6qbFF1u6RMx5WlpmB_46aeWQPcOLMs0wSoTED6Gq0&data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207523131%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=g3IqD53R53SytRGIfA1bZND8umdRmOJFgLeKBXVvISQ%3D&reserved=0\" rel=\"noopener\" target=\"_blank\">LifewithMCT8deficiency.com<\/a>.<br \/><strong>\u00a0<\/strong><br \/><strong>Important Safety Information<\/strong><br \/><strong>BOXED WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS<\/strong><br \/><strong>Contraindications:<\/strong> EMCITATE is contraindicated in patients with primary hyperthyroidism.<br \/><strong>\u00a0<\/strong><br \/><strong>Warnings and precautions<\/strong><\/p>\n<p>\u25cf\u00a0<strong>Thyrotoxicosis:<\/strong> Signs and symptoms of thyrotoxicosis, including increased heart rate, elevated blood pressure, diarrhea, hyperhidrosis, irritability, insomnia and nightmares, have occurred during treatment initiation and dose titration. Monitor patients and adjust the EMCITATE dose as indicated.<br \/>\u25cf\u00a0<strong>Laboratory test interference for T3 measurement:<\/strong> Tiratricol can cross-react with immunoassays for T3, leading to unreliable T3 results and overestimation of T3.<\/p>\n<p><strong>Adverse reactions:<\/strong> The most common adverse reactions (\u22655 %) are diarrhea, vomiting, rash and hyperhidrosis.<br \/>To report suspected adverse reactions, contact Egetis Therapeutics US Inc. at 1-844-4EGETIS (1-844-434-3847) or the FDA at 1-800-FDA-1088 or<a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.fda.gov%26t%3Dh.eJxFzEsOgyAUheGtGMYNVHkVR27lChdpCmoMSk3TvTekTTo9_8n3IvsWSd-QkPPaM1ZKod4BnZaDJXQFsg3k0pBH_Rxo87KdLCLCPNO0b2s4h9-an9QuiY0SR6c0By0kqpE74C1aaTz3GlAY1mrTCXXlN0mVEq3qTPWx-hG-pBymBPdYvdpcbf_l_QGxgzhZ.MEUCIGwmDLgOpbTorJpKGnqkhEC08vn9CYT2zKuYs1CAJ34tAiEA0P_Ca3ZdskwDJjHtAeKrqA1_BJsXMHgebYmBSEbyW5Y&data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207547606%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=tZ%2ByoYo0HXT0SMF9vcb1ifgONUb6a3h8Q6p6oxj%2Fe8o%3D&reserved=0\" rel=\"noopener\" target=\"_blank\"> www.fda.gov\/medwatch<\/a>.<\/p>\n<p><strong>Please see the full Prescribing Information:<\/strong><a href=\"https:\/\/eur04.safelinks.protection.outlook.com\/?url=https%3A%2F%2Flink.eu.inky.net%2Flink%3Fdomain%3Dwww.egetis.com%26t%3Dh.eJxFzduOwiAUheFXMVxPYSqFTr3yVXZhU8lwCt21Yya-u0FNvP1X8q1_ttXATgd2ISrrSYh93zkuSH7lJkexl87kRJhIbCVksKvAaDwBYee2ELpScTXVzz4tnU8u1wjkc-LFOvZ1YL_NvqKhXG8iIEJKPG61XG7nd6W_59GscLZ6lDAOCvUsLcgejZqcdCPgMIl-nI6D_pY_ims99Po4NR-bH-BFqvMSwYfmtc227VPuD0rFTlk.MEQCIC_USug_zF2pxnijA76can_m8hy5uKqPlEVeGhwdcn96AiBa-iLK80TlSh3VCbbpLLKexX0cTp_2AE4Db63spOhogQ&data=05%7C02%7Cleeann.murphy%40vectorytx.com%7C749eb81b26b34499c81708df2e4b0656%7C48c522b05e5d4e2184f06ff6ad85c432%7C0%7C0%7C639280572207571099%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=KPbzcRri95K8lJflYYHUD8Xm96OhlLvcaBQGTxU%2B3f0%3D&reserved=0\" rel=\"noopener\" target=\"_blank\"> https:\/\/www.egetis.com\/wp-content\/uploads\/emcitate-full-prescribing-information.pdf<\/a><br \/><strong>\u00a0<\/strong><br \/><strong>Om Egetis Therapeutics<\/strong><br \/>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov. <\/p>\n<p>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA.<\/p>\n<p>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar. F\u00f6r mer information, bes\u00f6k www.<a href=\"http:\/\/www.egetis.com\" rel=\"noopener\" target=\"_blank\">egetis.com<\/a> och f\u00f6lj Bolaget p\u00e5 LinkedIn.<br \/><strong><br \/><\/strong><strong>About PANTHERx Rare<\/strong><br \/>PANTHERx Rare makes rare disease care more personalized and less overwhelming by focusing on each patient and each therapy. PANTHERx experts develop relationships with patients, prescribers and pharmaceutical partners, serving as trusted advocates to support collaboration and care. Founded in Pittsburgh, Pennsylvania, in 2011, PANTHERx has grown into the largest independent rare pharmacy in the U.S. PANTHERx is licensed in all 50 states and U.S. territories and was the first national pharmacy to achieve dual rare disease accreditations from the Accreditation Commission for Health Care (ACHC) and the Utilization Review Accreditation Commission (URAC). PANTHERx received the 2026 MMIT Patient Choice Award for patient satisfaction, marking its ninth win.<\/p>\n<p>F\u00f6r mer information, bes\u00f6k <a href=\"http:\/\/www.pantherxrare.com\" rel=\"noopener\" target=\"_blank\">www.pantherxrare.com.<\/a><br \/><strong>\u00a0<\/strong><br \/><strong>F\u00f6r mer information, v\u00e4nligen kontakta<\/strong><br \/>Nicklas Westerholm, CEO<br \/>+46 (0) 733 542 062<br \/><a href=\"mailto:nicklas.westerholm@egetis.com\" rel=\"noopener\" target=\"_blank\">nicklas.westerholm@egetis.com<\/a><\/p>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications & Business Development<br \/>+46 (0) 733 011 944<br \/><a href=\"mailto:karl.hard@egetis.com\" rel=\"noopener\" target=\"_blank\">karl.hard@egetis.com<\/a><br \/><strong>\u00a0<\/strong><br \/><strong>Fram\u00e5tblickande uttalanden<\/strong><br \/>Detta pressmeddelande inneh\u00e5ller fram\u00e5tblickande uttalanden i den mening som avses i till\u00e4mplig v\u00e4rdepapperslagstiftning, inklusive uttalanden avseende kommersialiseringen och tillg\u00e4ngligheten av Emcitate\u00ae (tiratricol) i USA, tidpunkten f\u00f6r och utfallet av en eventuell monetisering av Priority Review Voucher f\u00f6r s\u00e4llsynta pediatriska sjukdomar (Rare Pediatric Disease Priority Review Voucher), den f\u00f6rv\u00e4ntade kapaciteten i Bolagets infrastruktur f\u00f6r patient\u00e5tkomst och distribution, de f\u00f6rv\u00e4ntade f\u00f6rdelarna med Emcitate f\u00f6r patienter med MCT8-brist samt Bolagets \u00f6vergripande strategiska planer f\u00f6r utveckling och kommersialisering av behandlingar f\u00f6r s\u00e4llsynta sjukdomar. Fram\u00e5tblickande uttalanden kan i allm\u00e4nhet identifieras genom ord s\u00e5som \u201df\u00f6rv\u00e4ntar\u201d, \u201dbed\u00f6mer\u201d, \u201davser\u201d, \u201danser\u201d, \u201duppskattar\u201d, \u201dplanerar\u201d, \u201dkommer att\u201d, \u201dkan\u201d, \u201dskulle kunna\u201d, \u201dpotentiell\u201d eller liknande uttryck, \u00e4ven om inte alla fram\u00e5tblickande uttalanden inneh\u00e5ller s\u00e5dana ord.<br \/>Dessa uttalanden baseras p\u00e5 Bolagets nuvarande f\u00f6rv\u00e4ntningar, antaganden och bed\u00f6mningar per dagen f\u00f6r detta pressmeddelande och \u00e4r f\u00f6rem\u00e5l f\u00f6r risker, os\u00e4kerhetsfaktorer och andra omst\u00e4ndigheter som kan medf\u00f6ra att faktiska resultat avviker v\u00e4sentligt fr\u00e5n dem som uttryckligen eller underf\u00f6rst\u00e5tt anges i uttalandena. S\u00e5dana faktorer omfattar, men \u00e4r inte begr\u00e4nsade till, risker relaterade till den kommersiella lanseringen av och marknadsacceptansen f\u00f6r Emcitate i USA, Bolagets f\u00f6rm\u00e5ga att etablera och uppr\u00e4tth\u00e5lla en \u00e4ndam\u00e5lsenlig kommersiell infrastruktur, inklusive distributions-, patientst\u00f6ds- och ers\u00e4ttningsl\u00f6sningar, tidpunkten f\u00f6r och villkoren f\u00f6r en eventuell monetisering av Priority Review Voucher, vilken \u00e4r beroende av marknadsf\u00f6rh\u00e5llanden och tillg\u00e5ngen p\u00e5 intresserade k\u00f6pare, eventuella krav eller begr\u00e4nsningar efter marknadsgodk\u00e4nnande som kan komma att inf\u00f6ras av den amerikanska l\u00e4kemedelsmyndigheten FDA, Bolagets f\u00f6rm\u00e5ga att uppr\u00e4tth\u00e5lla regulatoriska godk\u00e4nnanden i USA och Europeiska unionen, konkurrens fr\u00e5n befintliga eller framtida behandlingar, Bolagets m\u00f6jlighet att s\u00e4kerst\u00e4lla tillr\u00e4cklig finansiering f\u00f6r sin verksamhet och sina kommersiella aktiviteter samt allm\u00e4nna ekonomiska, marknadsm\u00e4ssiga och aff\u00e4rsm\u00e4ssiga f\u00f6rh\u00e5llanden.<br \/>F\u00f6r en n\u00e4rmare beskrivning av risker och os\u00e4kerhetsfaktorer som kan p\u00e5verka Bolagets verksamhet och resultat h\u00e4nvisas till Bolagets senaste \u00e5rsredovisning samt \u00f6vriga handlingar som getts in till relevanta tillsynsmyndigheter och som finns tillg\u00e4ngliga p\u00e5 <a href=\"http:\/\/www.egetis.com.\" rel=\"noopener\" target=\"_blank\">www.egetis.com.<\/a><br \/>Bolaget \u00e5tar sig inte n\u00e5gon skyldighet att offentligt uppdatera eller revidera fram\u00e5tblickande uttalanden, vare sig till f\u00f6ljd av ny information, framtida h\u00e4ndelser eller av andra sk\u00e4l, annat \u00e4n vad som f\u00f6ljer av till\u00e4mplig lag eller regelverk.<br \/>\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/c0ed713f-c3c4-4520-9cd1-640d580e4f7c\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-r-i-usa-for-patienter-med-mct8-brist.pdf\" rel=\"noopener\" target=\"_blank\">Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy Stockholm den 27 oktober 2026 \u2013 Egetis Therapeutics AB (publ) ("Egetis" eller "Bolaget") (Nasdaq Stockholm: […]","protected":false},"template":"","class_list":["post-6519","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy Stockholm den 27 oktober 2026 \u2013 Egetis Therapeutics AB (publ) ("Egetis" eller "Bolaget") (Nasdaq Stockholm: […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/\",\"name\":\"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-27T13:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics","og_description":"EMCITATE \u00e4r den f\u00f6rsta och enda FDA-godk\u00e4nda behandlingen f\u00f6r perifer tyreotoxikos hos vuxna och pediatriska patienter med MCT8-brist i USA Egetis RareLink\u2122, det dedikerade patientst\u00f6dsprogrammet, erbjuder st\u00f6d kring tillg\u00e5ng till behandling, utbildning och v\u00e5rdkoordinering i samarbete med PANTHERx\u00ae Rare Pharmacy Stockholm den 27 oktober 2026 \u2013 Egetis Therapeutics AB (publ) ("Egetis" eller "Bolaget") (Nasdaq Stockholm: […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"8 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/","name":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-27T13:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-therapeutics-paborjar-lanseringen-av-emcitate-i-usa-for-patienter-med-mct8-brist\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis Therapeutics p\u00e5b\u00f6rjar lanseringen av EMCITATE\u00ae i USA f\u00f6r patienter med MCT8-brist"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6512,"date":"2026-10-21T16:00:00","date_gmt":"2026-10-21T16:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"egetis-nomination-committee-for-the-2027-annual-general-meeting","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","title":{"rendered":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm, Sweden, October 21, 2026. <\/strong>Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. <\/p>\n<p>The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April 14, 2026, comprises the following members:<\/p>\n<p>James Brush, appointed by Frazier Life Sciences<br \/>Peter Lindell, appointed by Cidro F\u00f6rvaltning AB<br \/>Peder Walberg, appointed by Cetoros AB<\/p>\n<p>Mats Blom, Chairman of the Board of Directors, will co-opt to the Nomination Committee.<\/p>\n<p>The Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board\u00b4s members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further, the Committee shall submit proposals regarding the process to appoint the Nomination Committee to the AGM in 2028.<\/p>\n<p>Shareholders who wish to submit proposals to the Nomination Committee can do so by email to <a href=\"mailto:info@egetis.com\" rel=\"noopener\" target=\"_blank\">info@egetis.com<\/a> (please label emails \u2018Nomination Committee\u2019). Proposals should be submitted no later than January 22, 2027.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-ec3fd745d984\">\n<p><strong class=\"mfn-heading-1\">For further information, please contact<\/strong><\/p>\n<hr\/>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications & Business Development<br \/>Lena Wange, Investor Relations Director<br \/><a href=\"mailto:ir@egetis.com\" rel=\"noopener\" target=\"_blank\">ir@egetis.com<\/a> <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">About Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics is a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases with significant unmet medical need. Combining scientific and clinical expertise with integrated late-stage development, regulatory and commercial capabilities and manufacturing expertise, Egetis is committed to delivering treatments and dedicated support to underserved patient communities.<br \/>The Company's lead product, EMCITATE\u00ae (tiratricol), is the first and only approved treatment for MCT8 deficiency, a rare and life-shortening genetic disorder, with marketing authorizations in the European Union and in the United States.<br \/>Headquartered in Stockholm, Sweden, with operations in the U.S. and Europe, Egetis is building a sustainable global rare disease company.<br \/>For more information, visit egetis.com and follow the Company on LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Attachments<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/e0771fb3-5303-4fdf-9536-ee251d67628d\/egetis-nomination-committee-for-the-2027-annual-general-meeting.pdf\" rel=\"noopener\" target=\"_blank\">Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April […]","protected":false},"template":"","class_list":["post-6512","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-nomination"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/\",\"name\":\"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-21T16:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-nomination-committee-for-the-2027-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics","og_description":"Stockholm, Sweden, October 21, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2027 Annual General Meeting (AGM) to be held on May 12, 2027. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting held on April […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/","name":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-21T16:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-nomination-committee-for-the-2027-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis\u2019 Nomination Committee for the 2027 Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6512","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}},{"id":6513,"date":"2026-10-21T16:00:00","date_gmt":"2026-10-21T16:00:00","guid":{"rendered":"https:\/\/www.egetis.com\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/"},"modified":"2026-10-27T13:23:36","modified_gmt":"2026-10-27T13:23:36","slug":"egetis-valberedning-utsedd-infor-arsstamman-2027","status":"publish","type":"mfn_news","link":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","title":{"rendered":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong>Stockholm den 21 oktober 2026.<\/strong> Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027.<\/p>\n<p>Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar:<\/p>\n<p>James Brush, utn\u00e4mnd av Frazier Life Sciences<br \/>Peter Lindell, utn\u00e4mnd av Cidro F\u00f6rvaltning AB<br \/>Peder Walberg, utn\u00e4mnd av Cetoros AB<\/p>\n<p>Styrelsens ordf\u00f6rande Mats Blom \u00e4r adjungerad till valberedningen.<\/p>\n<p>Valberedningens uppgift \u00e4r att presentera f\u00f6rslag ang\u00e5ende ordf\u00f6randen och \u00f6vriga medlemmar i styrelsen, samt ers\u00e4ttning till styrelsens medlemmar, till \u00e5rsst\u00e4mman. Valberedningen ska \u00e4ven l\u00e4mna f\u00f6rslag ang\u00e5ende utn\u00e4mning och ers\u00e4ttning av revisorer. Vidare ska valberedningen l\u00e4mna f\u00f6rslag ang\u00e5ende processen f\u00f6r att utse valberedningen till \u00e5rsst\u00e4mman 2028.<\/p>\n<p>Aktie\u00e4gare som \u00f6nskar l\u00e4mna f\u00f6rslag till valberedningen kan g\u00f6ra det via e-post till info@egetis.com (v\u00e4nligen m\u00e4rk e-postmeddelanden med 'Valberedningen'). F\u00f6rslag ska vara inl\u00e4mnade senast den 22 januari 2027.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-ec3fd745d984\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta<\/strong><\/p>\n<hr\/>\n<p>Karl H\u00e5rd, Head of Investor Relations, Communications & Business Development<br \/>Lena Wange, Investor Relations Director<br \/><a href=\"mailto:ir@egetis.com\" rel=\"noopener\" target=\"_blank\">ir@egetis.com<\/a> <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-cef580f51688\">\n<p><strong class=\"mfn-heading-1\">Om Egetis Therapeutics<\/strong><\/p>\n<hr\/>\n<p>Egetis Therapeutics \u00e4r ett l\u00e4kemedelsbolag i kommersiell fas med fokus p\u00e5 att utveckla och tillhandah\u00e5lla innovativa behandlingar f\u00f6r patienter med s\u00e4llsynta sjukdomar d\u00e4r det finns betydande medicinska behov. <br \/>Genom att kombinera vetenskaplig och klinisk expertis med integrerade kompetenser inom sen klinisk utveckling, regulatoriska processer, kommersialisering och tillverkning \u00e4r Egetis engagerat i att tillhandah\u00e5lla behandlingar och dedikerat st\u00f6d till patientgrupper med stora medicinska behov och begr\u00e4nsade behandlingsalternativ. <br \/>Bolagets ledande produkt, EMCITATE\u00ae (tiratricol), \u00e4r den f\u00f6rsta och enda godk\u00e4nda behandlingen f\u00f6r MCT8-brist, en s\u00e4llsynt och livsf\u00f6rkortande genetisk sjukdom, med marknadsgodk\u00e4nnande i EU och i USA. <br \/>Med huvudkontor i Stockholm och verksamhet i USA och Europa bygger Egetis ett h\u00e5llbart globalt l\u00e4kemedelsbolag inom s\u00e4llsynta sjukdomar.<br \/>F\u00f6r mer information, bes\u00f6k egetis.com och f\u00f6lj bolaget p\u00e5 LinkedIn.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/d8486af4-1140-4613-8531-279cdf1fe3bc\/egetis-valberedning-utsedd-infor-arsstamman-2027.pdf\" rel=\"noopener\" target=\"_blank\">Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"Stockholm den 21 oktober 2026. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027. Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar: James Brush, utn\u00e4mnd av Frazier Life SciencesPeter […]","protected":false},"template":"","class_list":["post-6513","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn","mfn-news-tag-mfn-ci-nomination","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:type\" content=\"article\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:title\" content=\"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:description\" content=\"Stockholm den 21 oktober 2026. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027. Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar: James Brush, utn\u00e4mnd av Frazier Life SciencesPeter […]\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:site_name\" content=\"Egetis Therapeutics\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-27T13:23:36+00:00\" class=\"yoast-seo-meta-tag\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:site\" content=\"@Egetis_EGTX\" class=\"yoast-seo-meta-tag\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" class=\"yoast-seo-meta-tag\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" class=\"yoast-seo-meta-tag\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/\",\"name\":\"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\"},\"datePublished\":\"2026-10-21T16:00:00+00:00\",\"dateModified\":\"2026-10-27T13:23:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/egetis-valberedning-utsedd-infor-arsstamman-2027\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN-nyheter\",\"item\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#website\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"name\":\"Egetis Therapeutics\",\"description\":\"Vi \\\"tar hand om de s\u00e4llsynta\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#organization\",\"name\":\"Egetis Therapeutics\",\"url\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"contentUrl\":\"http:\\\/\\\/www.egetis.com\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/egetis-logo.svg\",\"width\":246,\"height\":54,\"caption\":\"Egetis Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/www.egetis.com\\\/sv\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Egetis_EGTX\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/egetis-therapeutics-ab\",\"https:\\\/\\\/youtube.com\\\/@MCT8Deficiency\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","og_locale":"sv_SE","og_type":"article","og_title":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics","og_description":"Stockholm den 21 oktober 2026. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) meddelade idag sammans\u00e4ttningen av valberedningen inf\u00f6r \u00e5rsst\u00e4mman som kommer att h\u00e5llas den 12 maj 2027. Valberedningen, som har utsetts i enlighet med de principer som antogs av \u00e5rsst\u00e4mman den 14 april 2026, best\u00e5r av f\u00f6ljande medlemmar: James Brush, utn\u00e4mnd av Frazier Life SciencesPeter […]","og_url":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","og_site_name":"Egetis Therapeutics","article_modified_time":"2026-10-27T13:23:36+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.egetis.com\/wp-content\/uploads\/2026\/08\/egetis-share-image.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Egetis_EGTX","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","url":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/","name":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027 - Egetis Therapeutics","isPartOf":{"@id":"https:\/\/www.egetis.com\/sv\/#website"},"datePublished":"2026-10-21T16:00:00+00:00","dateModified":"2026-10-27T13:23:36+00:00","breadcrumb":{"@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.egetis.com\/sv\/news\/egetis-valberedning-utsedd-infor-arsstamman-2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/www.egetis.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN-nyheter","item":"https:\/\/www.egetis.com\/sv\/news\/"},{"@type":"ListItem","position":3,"name":"Egetis valberedning utsedd inf\u00f6r \u00e5rsst\u00e4mman 2027"}]},{"@type":"WebSite","@id":"https:\/\/www.egetis.com\/sv\/#website","url":"https:\/\/www.egetis.com\/sv\/","name":"Egetis Therapeutics","description":"Vi \"tar hand om de s\u00e4llsynta","publisher":{"@id":"https:\/\/www.egetis.com\/sv\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.egetis.com\/sv\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/www.egetis.com\/sv\/#organization","name":"Egetis Therapeutics","url":"https:\/\/www.egetis.com\/sv\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/","url":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","contentUrl":"http:\/\/www.egetis.com\/wp-content\/uploads\/2023\/04\/egetis-logo.svg","width":246,"height":54,"caption":"Egetis Therapeutics"},"image":{"@id":"https:\/\/www.egetis.com\/sv\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/Egetis_EGTX","https:\/\/www.linkedin.com\/company\/egetis-therapeutics-ab","https:\/\/youtube.com\/@MCT8Deficiency"]}]}},"_links":{"self":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.egetis.com\/sv\/wp-json\/wp\/v2\/media?parent=6513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}]